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ABSTRACT

THE FIBRONECTIN EIIIA SPLICE VARIANT PROMOTES HEPATIC
STELLATE CELL MOTILITY AND LIVER FIBROSIS VIA α 9β 1 INTEGRIN

Abby L. Olsen
Rebecca G. Wells

Cellular fibronectin that contains the alternatively spliced extra domain A (EIIIA+
cFN) is upregulated after liver injury and has been reported to promote myofibroblast
differentiation of precursor cells from liver, lung, and skin. We examined the role of
EIIIA+ cFN in liver fibrosis induced by thioacetamide toxicity and by bile duct ligation.
Surprisingly, EIIIA-/- and wild type mice were equally susceptible to fibrosis after bile
duct ligation, but not after thioacetamide. We therefore studied the effects of EIIIA+ cFN
on two major myofibroblast precursor populations in the liver, hepatic stellate cells and
portal fibroblasts, which we suggest are the dominant cellular mediators of hepatic versus
biliary fibrosis, respectively. Using a mechanically physiologic cell culture system, we
found that EIIIA+ cFN was not required for myofibroblast differentiation of either cell
type, but had cell-specific effects on motility. Hepatic stellate cells cultured on cFN were
more motile than cells on plasma fibronectin (pFN), which lacks EIIIA, and this
increased motility was dependent on EIIIA and its specific receptor, integrin α9β1. Portal
fibroblasts, in contrast, expressed little α9β1 and demonstrated no motility increase on
EIIIA+ cFN compared to pFN. These data demonstrate that myofibroblast populations
iv

have significant functional differences regulated by subtle changes in the matrix
environment, and they suggest that variable responses to matrix proteins may drive
different forms of fibrosis.
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Chapter 1:
Introduction

Liver fibrosis is clinically significant

Liver fibrosis, and its end result, cirrhosis, represent the final common outcome of
chronic liver injury due to a wide variety of causes (Figure 1-1). In the United States, the
most common causes of liver fibrosis are alcohol, viral hepatitis, and non-alcoholic
steatohepatitis (NASH). Collectively, these entities are a source of significant morbidity
and mortality, with chronic liver disease or cirrhosis listed as the primary cause for
112,000 hospital discharges and 29,165 deaths, annually1. Treating liver fibrosis at early
to moderate stages has been an elusive goal, complicated by an inability to reliably detect
early disease, a lack of understanding as to which patients will develop progressive
fibrosis and cirrhosis, and an absence of effective therapies. Thus it is not surprising that
greater than 6,000 liver transplants are performed annually in the United States2, with
another approximately 17,000 patients languishing on the waiting list, many of whom
will die before receiving a liver (Scarborough et al., 2008).

Fibrosis is caused by myofibroblasts

Liver fibrosis, as well as similar processes in the skin, lung, kidney, and arteries,
can be thought of as pathologic variants of the normal physiologic process of wound
1

Centers for Disease Control and Prevention. National Center for Health Statistics. Health Data Interactive.
www.cdc.gov/nchs/hdi.htm.
2
Transplants in the U.S. by recipient gender. Organ Procurement and Transplantation Network website.
http://optn.transplant.hrsa.gov/latestData/rptData.asp. Updated September 11, 2009.
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Figure 1-1. The many causes of liver fibrosis. The most common causes of liver
fibrosis are chronic alcohol use, viral hepatitis, non-alcoholic steatohepatitis (NASH),
and autoimmune disease. This figure has been modified from one originally created by
former lab member Erick P. Chan, M.D.!
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healing. In each of these systems, the cells responsible for the pathology are
myofibroblasts (Hinz et al., 2007). Classically, myofibroblasts are defined by the
expression of α smooth muscle actin (αSMA), a mechanosensitive actin isoform that is
incorporated into stress fibers (Goffin et al., 2006), as well as by the production and
contraction of the extracellular matrix (ECM), particularly collagen I. Although αSMA is
widely accepted as the quintessential myofibroblast marker, recent lineage tracing studies
suggest that its expression is not always synonymous with being a collagen-producing
cell (Magness et al., 2004), and there are ongoing efforts to identify more markers that
distinguish a true myofibroblast from smooth muscle cells and general fibroblasts (Hinz,
2009).
Myofibroblasts differentiate from other cell types as part of a generalized injury
response. Cells of surprisingly diverse lineages have been identified as myofibroblast
precursors, including resident fibroblasts, smooth muscle cells (Hao et al., 2006) and
pericytes (Rajkumar et al., 2005), as well as possibly bone marrow derived cells (Abe et
al., 2001; Direkze et al., 2003; Schmidt et al., 2003), and epithelial cells (Kim et al.,
2006; Zeisberg and Kalluri, 2004). Of these, fibroblasts are the most common and have
been the best studied. Although there is tissue type specificity to the process, generally,
the differentiation of fibroblasts to myofibroblasts is a two-step process, involving both
soluble growth factors and mechanical tension. First, mechanical tension and platelet
derived growth factor (PDGF) signaling are required for the differentiation of fibroblasts
to proto-myofibroblasts, which in turn differentiate to full αSMA-expressing
myofibroblasts in response to even greater mechanical tension and transforming growth
factor β (TGFβ) signaling (Malmstrom et al., 2004; Tomasek et al., 2002).
3

Myofibroblasts in the liver

In the liver, hepatic stellate cells have long been considered to be the predominant
myofibroblast precursor cells, although as is true generally, they are not alone (Figure 12) (Friedman, 2008a). Portal fibroblasts, other endogenous cells, and bone marrowderived cells (Choi and Diehl, 2009; Forbes et al., 2004; Li et al., 2007; Russo et al.,
2006) may contribute to the myofibroblast pool, particularly in biliary fibrosis (Beaussier
et al., 2007). In the healthy liver, hepatic stellate cells reside in the perisinusoidal space,
or the Space of Disse, between the anti-luminal side of sinusoidal endothelial cells and
the basal side of hepatocytes (Figure 1-3) (Friedman and Arthur, 2002). Their primary
function is to store retinoids, though they have also been implicated in diverse processes
such as liver development and regeneration, immunoregulation of the liver, and cytokine
secretion, and they may function as specialized adiopcytes or pericytes (Friedman,
2008a). In contrast, little is known about the role of portal fibroblasts in healthy liver
(Dranoff and Wells, 2010).
The two most important growth factors controlling hepatic stellate cell
myofibroblast differentiation and behavior are PDGF and TGFß, which have been
proposed to have different yet synergistic functions in liver fibrosis. Generally, PDGF is
considered to be more important in control of proliferation and motility, whereas TGFß is
more important for acquisition of stress fibers and contraction of the ECM (Friedman,
1999, 2008b); a similar segregation of roles is see in other cell types as well (Chan et al.,
2009). Hepatic stellate cells upregulate both PDGFRβ and PDGF-BB as they
4

Figure 1-2. Sources of myofibroblasts in liver injury. Multiple sources of fibrogenic
myofibroblasts are likely in liver injury depending on the site and nature of the injury.
While resident stellate cells appear to be the most likely source, peri-portal fibroblasts
may be especially prominent in biliary injury, whereas bone marrow and possible
epithelial-mesenchymal transition may contribute as well. Friedman. Physiological
Reviews, 2008, Am. Physiol. Soc. used with permission.!
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Figure 1-3. Location of hepatic stellate cells in normal liver. Diagram of the hepatic
sinusoid demonstrating the relative orientation of stellate cells (in blue, indicated with
arrows) within the sinusoidal architecture. Kupffer cells are indicated in mauve.
Friedman. Science Medicine 2002, as reprinted in Friedman. Physiological Reviews,
2008. Used with permission. !
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differentiate, creating a autocrine signaling loops (Pinzani et al., 1989). There is also
evidence for crosstalk between PDGF and TGFβ in hepatic stellate cells, in that TGFβ
causes increased transcription of PDGFRβ (Pinzani et al., 1995), and stimulation of
connective tissue growth factor (CTGF) production by PDGF can be inhibited by
blocking TGFβ (Paradis et al., 2002).
TGFβ promotes hepatic stellate cell differentiation primarily by inducing
phosphorylation of similar to mothers against decapentaplegic 3 (Smad3) by transforming
growth factor beta receptor 1 (TGFβR1), which in turn increases αSMA, collagen I, and
fibronectin expression (Liu et al., 2003; Uemura et al., 2005). Interestingly, treatment of
hepatic stellate cells with both PDGF and TGFβ induces greater phosphorylation of
Smads 2 and 3 by c-Jun N-terminal kinase (JNK) than treatment with either growth factor
alone (Yoshida et al., 2005), suggesting another level of possible synergy. Far less is
known about the growth factor requirements for non-stellate cell myofibroblast
precursors, with the exception that TGFβ is clearly required for myofibroblast
differentiation of portal fibroblasts (Li et al., 2007).

Alternative fibronectin isoforms

As with other myofibroblast precursors, hepatic stellate cells are affected not only
by growth factor signaling but also directly by the chemical and mechanical properties of
their microenvironment, to which they are exquisitely sensitive. Among the many ECM
proteins that are upregulated in liver fibrosis is fibronectin, a modular glycoprotein
composed of repeating units of type I, II, and III repeats (Figure 1-4A). There are two
7
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Figure 1-4. Schematic of fibronectin isoforms. Type 1 repeats are blue, type 2
repeats are orange, and type 3 repeats are pink. A. Fibronectin is secreted as a
soluble, disulfide bonded dimer. In pFN, one monomer contains the IIICS region and
the other does not (shown). In cFN, both monomers contain the IIICS region. Areas of
fibronectin that bind to extracellular matrix proteins, including fibronectin itself, are
denoted. B. There are three potential regions of alternative splicing in cFN: EIIIB may
be spliced in between type III repeats 7 and 8, EIIIA may be spliced in between type III
repeats 11 and 12, and there are 5 splicing possibilities for the IIICS region. !

8

types of fibronectin, termed plasma fibronectin (pFN) and cellular fibronectin (cFN),
which are encoded by a single gene product but differ from in many ways, including
tissue and developmentally specific expression patterns, cell of origin, quaternary
structure, posttranslational modifications, and alternative splicing (Table 1-1). Only
alternative splicing will be discussed in detail here.
Multiple areas of alternative splicing exist for fibronectin (Schwarzbauer et al.,
1987; Schwarzbauer et al., 1983). First, there are two alternative type III repeats, termed
extra domain A (EDA, in the human, or EIIIA, in the rodent) and extra domain B (EDB,
in the human, or EIIIB, in the rodent). For clarity, the rodent nomenclature will be used
throughout this manuscript. Additionally, there is a an area near the C-terminus, termed V
in the human or IIICS in the rodent, that has a complicated, species-specific, splicing
pattern, and will not be further discussed here. In combination, these alternative splicing
events can result in up to 20 different FN isoforms (Figure 1-4B).
Whereas pFN constitutively excludes the alternatively spliced EIIIA and EIIIB
domains, individual cFN monomers may include any combination of EIIIA and EIIIB.
While EIIIA+ cFN and EIIIB+ cFN are expressed at very low levels in most healthy
tissue (Peters et al., 1996), including liver, it has long been known that EIIIA+ cFN, and
to a lesser extent, EIIIB+ cFN, is upregulated in response to liver injury (Jarnagin et al.,
1994). However, whether these isoforms play an active role in the disease pathology or
whether they are simply markers of injury has not been established. Outside of the liver,
the potential requirement for EIIIA+ cFN in wound healing and fibrosis has been more
thoroughly investigated. EIIIA+ cFN has been implicated in the differentiation of
myofibroblast precursors to protomyofibroblasts (Dugina et al., 2001), and it has
9

EIIIA/EIIIB
splicing
Glycosylation

pFN
EIIIA and EIIIB are never
included

Cell of origin

No fucose or terminal
galactose; terminal
carbohydrates are topped by
sialic acid
Hepatocytes

Structure

Soluble dimer

IIICS splicing

IIIICS domain is included on
one monomer of dimer

cFN
EIIIA and EIIIB are included during
development and disease but
(mostly) excluded in healthy adults
Includes fucose and terminal
galactose; terminal carbohydrates
lack sialic acid
Fibroblasts, myofibroblasts,
endothelial cells, rarely epithelial
cells
Secreted as soluble dimer but
assembled into insoluble fibrils
Both monomers in a dimer include
IIICS

Table 1-1. Differences between pFN and cFN. pFN and cFN differ in splicing, cell of
origin, glycosylation pattern, and structure. Of note, differences in glycosylation mean
that only cFN serves as a ligand for the hepatocyte asialoglycoprotein receptor, which
induces cytokine secretion by injured hepatocytes (Aziz-Seible et al., 2011).
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clearly been shown to be required for their subsequent differentiation to myofibroblasts in
the skin as well as the lung (Muro et al., 2008; Serini et al., 1998). There is also limited
evidence for a role for EIIIA+ cFN in hepatic stellate cell myofibroblast differentiation,
in that EIIIA+ cFN produced by sinusoidal endothelial cells has been reported to increase
expression of αSMA by hepatic stellate cells (Jarnagin et al., 1994).

How do EIIIA+ cFN and EIIIB+ cFN exert their effects?

How might EIIIA+ cFN promote myofibroblastic differentiation? Several lines of
evidence point to cooperation with TGFβ (Figure 1-5). First, TGFβ promotes splicing in
of EIIIA in cFN in many cell types (Baelde et al., 2004; Hackett et al., 2009; Inoue et al.,
1999; Li et al., 2000), including hepatic stellate cells (Chang et al., 2004; George et al.,
2000), though, interestingly, TGFβ is a negative regulator of EIIIA splicing in
chondrocytes (Han et al., 2005; Han et al., 2007). Second, EIIIA+ cFN is required for
TGFβ-dependent induction of αSMA expression in dermal myofibroblasts, which secrete
EIIIA+ cFN and incorporate it into fibrils in a process that requires stress fiber
contractility (Dugina et al., 2001). Finally, αSMA-expressing myofibroblasts liberate
latent TGFβ from the extracellular matrix (Wipff et al., 2007), a process that is deficient
in EIIIA-/- pulmonary myofibroblasts (Muro et al., 2008).
Far less is known about the potential role of EIIIB+ cFN in fibrosis than that of
EIIIA+ cFN, but it is interesting to note that there is a difference in the timing of their
expression in liver fibrosis, with EIIIB+ cFN being upregulated later than EIIIA+ cFN, at
least as detectable in whole liver lysates (Jarnagin et al., 1994). Recent preliminary
11
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Figure 1-5. Evidence for feedback between TGF!, EIIIA+ cFN, and "SMA. A
multitude of evidence in the literature supports a role for EIIIA+ cFN in mediating the
effects of TGF!, and vice versa. References for these claims are included in the main
text. #
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data from our lab suggest earlier, focal upregulation of EIIIB in two rat models of fibrosis
(data not shown). Together, these differences in the spatiotemporal upregulation of
EIIIA+ cFN and EIIIB+ cFN suggest that they might have different effects on hepatic
stellate cells or fibrosis in general. Additionally, EIIIB is known to be an excellent
marker of both physiologic vasculogenesis as well as pathologic angiogenesis (Astrof and
Hynes, 2009), a process that also occurs in the later stages of liver fibrosis.
The study of EIIIA and EIIIB has been advanced by the relatively recent
generation of EIIIA-/- and EIIIB-/- mice, as well as an EIIIA/EIIIB double knockout
mouse. EIIIA-/- mice were independently engineered by two groups (Muro et al., 2003;
Tan et al., 2004); surprisingly, the mice were normal and fertile, as were EIIIB-/- mice
(Fukuda et al., 2002), despite the ubiquitous expression of both isoforms during
development (Peters and Hynes, 1996) and the early embryonic lethality of the total FN-/mouse (George et al., 1993). An EIIIA-/-, EIIIB-/- double knockout mouse nearly
phenocopied the complete FN-/- mouse, with most mice succumbing to severe
cardiovascular defects at E10.5, although this phenotype was pleiotrophic and strain
specific (Astrof et al., 2007).
These findings, along with the ability of EIIIA and EIIIB to compensate for one
another in both physiologic and tumor angiogenesis (Astrof et al., 2004), support a model
in which EIIIA and EIIIB are essential, yet redundant. However, other evidence suggests
independent functions for each domain. EIIIA and EIIIB are very highly conserved
across species (for example, the amino acid sequence of EIIIA is >92% identical across
all mammals), yet they share only 30% amino acid sequence within a given species.
Additionally, EIIIA and EIIIB knockout mice do have distinct phenotypes as adults.
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EIIIA-/- mice have reduced susceptibility to atherosclerosis (Babaev et al., 2008; Tan et
al., 2004), reduced susceptibility to pulmonary fibrosis (Muro et al., 2008), a shorter life
span (Muro et al., 2003), defective motor coordination (Chauhan et al., 2005), and
impaired cutaneous wound healing (Muro et al., 2003), yet no defect in fibronectin matrix
assembly, despite EIIIA having been shown to promote FN matrix assembly in vitro (Abe
et al., 2005). In contrast, EIIIB-/- mice exhibit defects in FN matrix assembly, along with
smaller fibril length and width, yet unlike EIIIA-/- mice, they have no abnormality in
wound healing (Fukuda et al., 2002).
Definitive mechanistic studies defining the requirements of each domain in a
given cellular process have been hampered by the lack of discovery or understanding of
EIIIA and EIIIB specific receptors. Fibronectins are modular proteins composed of
repeating subunits that bind multiple integrins; thus, one of the ways in which cFN may
exert its effects on cells is via unique integrin binding partners for the extra domains. In
support of this possibility is the fact that EIIIA has been shown to be a ligand for α4β1 and
α9β1 using in vitro integrin binding assays. This interaction may be physiologically
relevant, as cFN and α9β1 have been shown to be upregulated together at the dermalepidermal junction in wound healing (Singh et al., 2009; Singh et al., 2004) and during
lymphatic development (Bazigou et al., 2009). Integrin binding partners for EIIIB are less
well characterized: an EIIIB containing fragment functions as a ligand for αvβ3, but it is
unclear whether the integrin binds to EIIIB or the type III FN repeats surrounding it
(Adair et al., 2005). In addition to or instead of signaling through unique integrins, cFN
may exert its effects on cells by creating a higher affinity interaction with α5β1 (Manabe
et al., 1997) or by interacting with non-integrin receptors such as TLR-4
14

(Gondokaryono et al., 2007; Okamura et al., 2001).

Conclusion and Project Aims

In the literature, EIIIA+ cFN is widely cited as a requirement for myofibroblast
differentiation, and indeed there exists compelling evidence supporting a role for it in
differentiation of dermal and pulmonary myofibroblasts. However, evidence for its
putative role in hepatic stellate cell myofibroblast differentiation is limited to one report
demonstrating increased αSMA in stellate cells cultured on cFN, and there is no known
mechanism for this phenomenon. Additionally, whether EIIIA+ cFN is required for the
development of liver fibrosis in vivo has not been established. Thus, the primary goal of
this thesis was to define the requirement for EIIIA+ cFN in hepatic stellate cell
myofibroblast differentiation and liver fibrosis. Assuming that EIIIA did turn out to be
necessary, the secondary goal was to determine why.
We hypothesized that EIIIA+ cFN, by virtue of its ability to promote
myofibroblast differentiation, would be required for the development of liver fibrosis. To
test this hypothesis, we studied primary myofibroblast precursor cells in a mechanically
physiologic cell culture system to determine the mechanism of EIIIA function, and we
challenged EIIIA-/- mice in two models of liver fibrosis to confirm its relevance in vivo.
Surprisingly, we found that the requirement for EIIIA+ cFN depended on the gender of
the mice as well as the model of fibrosis used, with male, but not female, EIIIA-/- mice
being protected from thioacetamide-induced fibrosis, and neither gender being protected
from bile duct ligation-induced fibrosis (Chapter 3). In Chapter 4, we demonstrate that
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the differential requirement for EIIIA in these two models reflects differences in the
relative contribution of hepatic stellate cells versus portal fibroblasts in the models.
Surprisingly, neither of these cell types requires EIIIA+ cFN for myofibroblast
differentiation, but instead EIIIA+ cFN promotes motility of hepatic stellate cells. In
Chapter 5, we demonstrate that the EIIIA specific receptor, α9β1 integrin, is required for
this phenotype, and we explore potential downstream targets of α9β1. Finally, in Chapter
6 we present preliminary data suggesting that α9β1 does not confer any additional
adhesion to cFN. In Chapter 7, we conclude with a summary of the results and a
discussion of their implications for understanding myofibroblast behavior in liver
fibrosis.
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Chapter 2:
Materials and Methods

Antibodies and reagents

A rabbit polyclonal anti-α9 antibody provided as a kind gift by Dr. Cezary
Marcinkiewicz (Temple University) was used for immunohistochemistry and
immunoblotting (Staniszewska et al., 2008). Other antibodies used were α9β1 (for
adhesion blockade; clone Y9A2, Abcam), α5 (for immunoblotting, Millipore; for
adhesion blockade and immunostaining, clone HMα5-1, Santa Cruz), αv (for
immunoblotting, clone 21/CD51, BD Bioscience; for adhesion blockade, clone H9.2B8,
Santa Cruz), peptidylprolyl isomerase B (cyclophilin B, Thermo Scientific), αSMA
(clone 1A4, Sigma), vinculin (Sigma), desmin (clone DE-U-10, Sigma), elastin (Accurate
Chemical), total FN (for Western immunoblotting, clone 10/Fibronectin, BD Bioscience;
for immunostaining and adhesion blockade, clone C-20, Santa Cruz), EIIIA (for adhesion
blockade, Millipore; for adhesion blockade and immunostaining, clone IST9, Santa
Cruz), total PDGFRβ (Cell Signaling), and PDGFRβ phosphorylated on Y751 (Cell
Signaling).

Animal studies

The EIIIA-/- mice (which are on a pure C57Bl/6 background) were established
from a breeding pair resuscitated from cryopreserved embryos from the Mutant Mouse
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Regional Resource Center (MMRRC), strain name B6.129S4-Fn1tm1Bwg/Mmnc, originally
deposited by Dr. Elizabeth George (Tan et al., 2004). All animals were cared for in
compliance with the US Department of Health and Human Services Guide for the Care
and Use of Laboratory Animals and with the approval of the University of Pennsylvania
Institutional Animal Care and Use Committee.

Thioacetamide

Thioacetamide (200 mg/L) was prepared fresh every 3 days in sterile deionized
water and administered to mice for 12 weeks (Table 2-1) or 16 weeks (Table 2-2). Adult
mice of both sexes were used for all experiments.

Serum alanine amino transferase (ALT) measurement

50-250 µl whole blood was collected from mice at the time of euthanization by
cardiac puncture. Blood was centrifuged for 5 min at 5,000 rpm at 4° C to separate serum
from erythrocytes. If visible hemolysis occurred, samples were excluded from analysis,
as erythrocytes also express ALT. Serum ALT activity (U/L) was measured on a BioTek
Synergy 2 microplate reader using an NADPH-based absorbance assay, according to the
manufacturer’s instructions (Stanbio Laboratory). A normal serum ALT activity is < 38
U/L.
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Mouse

Sex

Genotype

Treatment

Age at sacrifice (weeks)

Weight (g)

100

F

+/+

TAA

32

23.9

101

F

+/+

TAA

32

24.7

102

F

+/-

TAA

32

23.6

103

F

+/-

TAA

32

24.1

104

F

+/+

TAA

32

26.2

105

F

+/+

TAA

32

24.2

152

F

+/-

H 2O

29

26.0

153

M

+/-

H 2O

27

32.2

154

M

Unknown

H 2O

27

30.0

161

M

+/-

TAA

26

25.3

164

M

+/-

TAA

26

25.1

166

M

+/-

TAA

24

15.0

167

M

-/-

TAA

24

28.5

168

M

+/-

TAA

24

25.7

169

M

-/-

TAA

24

23.2

186

M

+/-

TAA

19

27.2

187

M

+/+

TAA

19

25.3

188

M

+/-

TAA

19

26.7

189

M

+/-

TAA

20

31.6

190

M

+/+

TAA

20

26.0

191

M

-/-

TAA

20

28.2

193

M

-/-

H 2O

18

29.8

195

M

+/+

H 2O

18

30.3

206

F

-/-

TAA

18

24.1

207

F

+/-

TAA

18

23.2

209

M

+/-

H 2O

18

22.3

210

M

+/-

H 2O

18

20.1

211

F

-/-

TAA

18

31.1

216

F

+/+

TAA

18

26.1

336

M

+/-

TAA

18

27.3

337

M

-/-

TAA

18

24.4

338

M

-/-

TAA

18

24.7

339

M

+/-

TAA

18

25.5

351

M

+/+

TAA

18

26.0

19

352

M

+/-

TAA

18

26.4

353

M

+/-

TAA

18

26.5

354

F

-/-

H 2O

18

26.2

355

F

+/-

H 2O

18

23.2

356

F

+/-

H 2O

18

25.2

360

F

+/-

TAA

18

23.3

361

F

+/-

TAA

18

22.0

362

F

+/-

TAA

18

24.2

363

F

+/-

TAA

18

22.3

364

F

-/-

TAA

18

22.6

368

F

+/+

H 2O

18

22.9

369

F

+/+

H 2O

18

21.0

370

M

+/-

TAA

18

25.7

371

M

+/-

TAA

18

24.8

372

M

-/-

TAA

18

29.0

373

M

+/-

TAA

18

25.2

374

M

+/+

TAA

18

24.3

Table 2-1: Mice used for the 12 week thioacetamide time point. Mouse number, sex,
genotype, age at sacrifice (weeks), and weight (g) are indicated.
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Mouse

Sex

Genotype

Treatment

Age at sacrifice (weeks)

Weight (g)

106

F

+/-

TAA

36

27.3

113

F

-/-

TAA

36

25.4

114

F

+/+

TAA

36

26.9

116

F

+/-

TAA

36

25.7

117

F

+/-

TAA

36

23.3

144

F

-/-

TAA

35

29.4

145

F

+/+

TAA

34

24.6

146

F

+/+

TAA

34

25.0

151

F

+/+

H 2O

31

30.5

155

M

+/-

H 2O

31

31.2

156

M

-/-

H 2O

31

31.5

157

F

+/+

TAA

31

24.1

158

F

+/-

TAA

31

24.4

159

F

+/-

TAA

31

24.5

165

F

+/+

TAA

30

23.3

179

M

+/-

TAA

25

26.0

180

M

+/-

TAA

25

24.5

181

M

-/-

TAA

25

25.0

212

M

+/-

TAA

22

25.3

213

M

+/+

TAA

22

27.3

214

M

+/-

H 2O

22

34.0

215

M

+/-

H 2O

22

35.1

218

M

-/-

TAA

22

23.6

220

M

-/-

TAA

22

25.3

221

M

-/-

TAA

22

23.4

340

F

+/-

TAA

22

23.1

341

F

+/-

TAA

22

21.1

342

F

+/-

TAA

22

20.7

343

M

+/+

TAA

22

23.9

344

M

+/-

TAA

22

25.2

345

M

+/-

TAA

22

25.1

346

M

+/-

TAA

22

26.6

21

347

M

+/-

TAA

22

27.3

348

F

+/-

H 2O

22

24.3

349

F

+/-

H 2O

22

22.5

350

F

+/+

H 2O

22

23.2

357

M

+/-

TAA

22

29.2

358

M

+/-

TAA

22

25.8

359

M

+/+

TAA

22

26.3

365

M

+/-

H 2O

22

32.2

366

M

+/-

H 2O

22

33.0

367

M

+/-

H 2O

22

29.4

375

F

+/+

TAA

22

22.3

376

F

+/-

TAA

22

23.8

377

F

-/-

TAA

22

22.3

378

F

+/-

TAA

22

24.6

Table 2-2: Mice used in the 16 week thioacetamide time point. Mouse number, sex,
genotype, age at sacrifice (weeks) and weight (g) are shown.
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qRT-PCR

Cells were homogenized on QiaShredder columns (Qiagen), and total RNA was
purified using the RNeasy kit (Qiagen). Pieces of liver were homogenized in Trizol
reagent (Invitrogen) using the Bullet Blender (Next Advance). Total RNA was quantified
by spectrometry, and the same amount of RNA per sample was used in each experiment.
Super Scriptase III (Invitrogen) was used for reverse transcription. qRT-PCR with Fast
SYBR green (Applied Biosystems) was performed on an ABI StepOne Plus Real-Time
PCR System (Applied Biosystems). Results were quantified using the relative standard
curve method, with the exception of the thioacetamide data (Figures 3-1 to 3-7), for
which the ΔΔCt method was used due to a large number of samples. Expression was
normalized to control transcripts, as stated in each figure legend. 3 technical replicates
were used per sample. Primer sequences are listed in Table 2-3.

Immunohistochemistry and quantification of images

Fresh liver sections were fixed in 10% phosphate-buffered formalin overnight at 4° C,
then washed with PBS, transferred to 70% ethanol and sent to the Morphology Core of
the Center for Molecular Studies in Digestive and Liver Diseases for paraffin-embedding,
sectioning, and staining with hematoxylin and eosin. For immunohistochemistry, slides
were warmed to 60° C for 15 minutes, dewaxed, and microwaved in 10 mM citric acid
(pH 6.0) for 10 minutes for antigen retrieval. Endogenous peroxidases were quenched,
and slides were sequentially blocked using an Avidin/Biotin Blocking Kit (Vector
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Protein name

Gene
name

Species

Forward primer 5’  3’

Reverse primer 5’  3’

α4 integrin

Itga4

Rat

CCCAGGCTACATCGTTTTGT

ATGGGAGTGAGGATGTCTCG

α5 integrin

Itga5

Rat

AGGTGACGGGACTCAACAAC

GGGCATTTCAGGACTTGTGT

α9 integrin

Itga9

Rat

CACTGGTGCATGAAGTGGAC

TGTTGTAGACCTGGAGAGTG

αSMA

Acta2

Mouse

ATTGTGCTGGACTCTGGAGATGGT

TGATGTCACGGACAATCTCACGCT

αSMA

Acta2

Rat

TGTGCTGGACTCTGGAGATG

GAAGGAATAGCCACGCTCAG

αv integrin

Itgav

Rat

GCTGCCGTTGAGATAAGAGG

TGCCTTGCTGAATGAACTTG

β2 microglobulin

B2m

Mouse

TGGTCTTTCTGGTGCTTGTC

GGGTGGAACTGTGTTACGTAG

Collagen I

Col1a2

Mouse

TTCTCCTGGCAAAGACGGACTCAA

AGGAAGCTGAAGTCATAACCGCCA

Collagen I

Col1a2

Rat

TTCTCTACTGGTGAAACCTGC

ACCCCTTCTGCGTTGTATTC

Collagen III

Col3a1

Mouse

CCCCCAGGACCTACTGGCCC

GACCACGCCCACCGGGAAAG

Collagen III

Col3a1

Rat

GAAGTCTCTGAAGCTGATGGG

GGCCTTGCGTGTTTGATATTC

Collagen IV

Col4a1

Rat

AGTTCCCCGCCGTCTCTGTT

ACAATCACCCTTCGCAGCGG

EIIIA+ cFN

n/a
(splice
variant
of Fn1)

Mouse

AGTCAGTGTGGTTGCCTTG

CTGAACACTGGGTGCTATCC

EIIIB+ cFN

n/a
(splice
variant
of Fn1)

Rat

ATACCGTCATCCCAGAGGTG

TCATAGTCAATGCCGGGTTC

EIIIB+ cFN

n/a
(splice
variant
of Fn1)

Mouse

AGATGACAAGGAAAGTGCCC

GGTGGAAGAGTTTAGCGGG

Elastin

Eln

Mouse

AGTTCCTGGTGTTGGTCTTC

CCTTGGCTTTGACTCCTGTG

Fibronectin (total)

Fn1

Mouse

CTTTGTGGTCTCATGGGTCTC

AGCAGGTCAGGAATGTTCAC

Fibronectin (total)

Fn1

Rat

TCCATTCCACCTTATAACACCG

AACGATGCTTCCTGAGTCTG

Glucuronidase β

Gusb

Mouse

CACCCCTACCACTTACATCG

ACTTTGCCACCCTCATCC

Glyceraldehyde-3phosphate
dehydrogenase

Gapdh

Mouse

CTTTGTCAAGCTCATTTCCTGG

TCTTGCTCAGTGTCCTTGC

n/a (rRNA)

Rn18s

Mouse
and rat

CCCAGTAAGTGCGGGTCATAA

GATCCGAGGGCCTCACTAAAC

PDGFRβ

Pdgfrb

Mouse

GCGGCTGCTGGAGACACTGG

TCCCCAAGGGTGTGGGTGACA

Tenascin C

Tnc

Rat

TGACACCACCTCCTACAGCCTG

TCCAAACCCAGTGGCATAGGCCT

TGF-β1

Tgfb1

Mouse

CCTGAGTGGCTGTCTTTTGA

CGTGGAGTTTGTTATCTTTGCTG

TIMP-1

Timp1

Mouse

GGACCTGGTCATAAGGGCTA

TTTTAGCATCTTAGTCATCTTGATCTT

Vimentin

Vim

Mouse

TTTCTCTGCCTCTGCCAAC

TCTCATTGATCACCTGTCCATC

Table 2-3. Primers used for qRT-PCR. Primers were designed using the SciTools
function available on Integrated DNA Technologies website.
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Labs) and StartingBlock Blocking Buffer (Thermo Scientific) according to the
manufacturer’s instructions. Primary antibody was diluted in PBS supplemented with
0.1% BSA and 0.2% Triton X-100 (PBT) and applied overnight at 4° C. Antibodies used
include αSMA (1:500) and α9 (1:1000). Biotinylated secondary antibody (Vector Labs)
was diluted 1:200 in PBT and applied for 30 min at 37° C. Slides were developed using
HRP-conjugated ABC reagent and DAB Substrate Kit for Peroxidase (both from Vector
Labs), counterstained with Gill’s hematoxylin (Fisher), and dehydrated. Slides were
visualized microscopically using a Nikon E600 microscope and images were captured
using a CCD camera and IPLab software. In some cases, staining was quantified using
Adobe Photoshop software by selecting a range of color that was “brown,” and
calculating the number of brown pixels per field. The same definition of “brown” was
used for all slides that were directly compared. 4 randomly chosen fields per slide were
averaged.

Sirius red staining

Formalin-fixed paraffin-embedded liver sections were incubated for 1 hour at
room temperature in 0.1% Direct Red 80 (Sigma) in picric acid, then washed and
dehydrated. In some cases, slides were electronically scanned, and staining was
quantified using Adobe Photoshop by comparing the number of red pixels to the number
of total pixels in the liver section. When staining was not quantified, representative
photos are shown.
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Scoring of fibrosis

Degree of fibrosis was scored by a blinded observer using slides stained with
sirius red. We used a scoring system of 0-4, in which 0 represents no fibrosis, 1
represents mild fibrosis (some portal or sinusoidal fibrotic expansion), 2 represents
moderate fibrosis (much portal or sinusoidal fibrotic expansion but few bridges or septa),
3 represents severe fibrosis (numerous bridges or septa), and 4 represents cirrhosis.

Hydroxyproline measurement

Liver pieces (50-200 mg) were flash frozen in liquid nitrogen and stored at -80° C
until the time of the assay, then homogenized in 6 N HCl and incubated at 110° C for 2436 hours. The resulting slurry was incubated in chloramine T solution (1.45% chloramine
T, 10% n-propanol, and 0.5 M sodium acetate, pH 6.0) for 20 minutes at room
temperature. Ehrlich’s solution (1M p-dimethylaminobenzaldehyde, 70% n-propanol, and
30% perchloric acid) was then added, and the mixture was incubated for 15 minutes at
65° C. Absorbance at 555 nm was measured on a BioTek Synergy 2 microplate reader,
and hydroxyproline content in samples was quantified by comparing to absorbance
values for a standard curve composed of serial dilutions of trans-hydroxy-proline. Results
are expressed as total µg hydroxyproline per liver.
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Bile duct ligation

Wild type, heterozygous, and EIIIA-/- mice underwent ligation of the common bile
duct with placement of double ligatures, by standard techniques. Sham operated animals
(with manipulation of the bile duct but without ligation) served as negative controls.
Animals received prophylactic antibiotics (enrofloxacin, 0.5 mg/ml, administered via
drinking water) for 2 days prior to surgery and for an additional 7 days following surgery.
Animals received bupivicaine (2 mg/kg, administered subcutaneously) for local
anesthesia prior to surgery, and post-operative pain was managed with buprenorphine
(0.05-0.1 mg/kg, administered subcutaneously 5 hours post-operation) and meloxicam (5
mg/kg, administered orally daily for 3 days post-operaiton). Animals were sacrificed at 2
weeks (Table 2-4) or 4-6 days (Table 2-5) following bile duct ligation. Adult mice of
both sexes were used for all experiments.

Immunofluorescence on frozen tissue

Liver pieces were flash frozen in O.C.T. (Sakura) in liquid nitrogen and sent to
the Morphology Core of the Center for Molecular Studies in Digestive and Liver
Diseases for sectioning. Slides were warmed to room temperature, then blocked with
StartingBlock Blocking Buffer (Thermo Scientific). Primary anti-desmin antibody
(diluted 1:100 in PBS supplemented with 0.1% BSA and 0.2% Triton X-100) was applied
overnight at 4° C. Cy3-conjugated secondary antibody (Jackson Immunolabs) was
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Mouse

Sex

Genotype

Treatment

Age at sacrifice (weeks)

Weight (g)

29

F

+/-

BDL

17

17.7*

33

F

+/+

Sham

17

21.7

34

F

+/+

BDL

16

20.6*

38

M

+/-

Sham

11

26.0

41

M

-/-

Sham

11

23.0

42

M

+/-

BDL

11

24.0

43

F

+/+

BDL

16

22.3

48

F

-/-

BDL

18

21.2

49

F

+/+

Sham

18

20.3

50

F

+/-

BDL

18

21.6

51

M

+/+

Sham

14

23.9

54

M

+/-

Sham

14

24.5

56

M

+/+

BDL

14

19.6

57

M

-/-

BDL

14

22.1

58

M

+/-

BDL

14

19.1

59

M

+/+

BDL

14

19.3

63

F

+/+

BDL

17

18.5

64

M

+/-

BDL

14

22.9

65

F

+/+

Sham

17

23.4

66

F

+/-

BDL

17

18.1*

67

F

-/-

BDL

17

22.4

68

M

+/-

Sham

14

25.8

69

M

+/-

BDL

14

33.2*

84

M

+/-

BDL

14

19.0

87

M

+/-

Sham

21

26.8

90

M

+/-

BDL

21

30.5*

91

M

+/-

BDL

20

22.8

96

M

+/-

BDL

20

20.9

97

M

+/-

BDL

20

18.0

99

M

+/+

BDL

20

21.0

125

M

-/-

BDL

18

18.9

126

M

+/-

BDL

18

19.3

131

M

-/-

BDL

18

18.7

133

M

+/-

BDL

18

18.8

134

M

+/-

Sham

18

23.4

141

M

+/-

Sham

18

26.1

Table 2-4: Mice used for the 2 week bile duct ligation time point. Mouse number, sex,
genotype, age at sacrifice (weeks), and weight (g) are indicated. * = mice who developed
ascites.
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Mouse

Sex

Genotype

Treatment

Age at sacrifice (weeks)

Weight (g)

44

M

+/-

BDL

13

18.6

45

M

-/-

BDL

13

16.5

46

F

+/+

BDL

16

15.5

47

F

-/-

BDL

16

17.8

52

F

+/-

Sham

19

17.1

60

F

+/+

BDL

19

21.9

70

F

-/-

BDL

17

15.0

71

F

+/+

BDL

17

22.1

72

F

+/-

Sham

16

24.6

73

F

+/+

BDL

16

17.5

74

F

+/-

BDL

16

17.2

75

M

-/-

Sham

16

26.4

109

M

+/+

BDL

17

20.9

110

M

-/-

BDL

17

24.5

142

M

+/-

Sham

20

29.2

143

M

-/-

BDL

20

23.4

148

M

+/+

BDL

20

24.2

149

M

+/-

BDL

20

23.7

Table 2-5: Mice used in the 4-6 day bile duct ligation time point. Individual number,
sex, genotype, age at sacrifice, and post-operative weight (g) are listed.
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diluted 1:200 and applied for 30 minutes at 37° C. Slides were mounted with Fluorescent
Mounting Media (KPL) and visualized on a Nikon E600 microscope. Images were taken
with a CCD camera and IP Lab software.

Elastin staining

Formalin-fixed paraffin-embeded liver sections were dewaxed, then incubated in
0.5% hyaluronidase in TBS for 60 minutes at room temperature. Primary anti-elastin
antibody was diluted 1:100 in TBS with 3% BSA and 1% NGS and applied overnight at
4° C. Slides were blocked in TBS supplemented with 3% BSA and 0.9% NaCl for 20
minutes at room temperature. Endogenous peroxidase was quenched, and biotinylated
secondary anti-rabbit antibody diluted 1:200 in TBS was applied for 30 minutes at 37° C.
Signal was developed as described above for general immunohistochemistry.

Western immunoblotting for fibronectin

Recombinant pFN (from human plasma) and cFN (from human foreskin
fibroblasts) were purchased from BD, Millipore, or Sigma. 1 µg of each protein was
loaded per lane on a 6% SDS-PAGE gel (Invitrogen). Protein was transferred to a TransBlot Transfer Medium nitrocellulose membrane (Bio-Rad). The membrane was incubated
overnight at 4° C in primary anti-fibronectin antibody diluted 1:5000 in 1% milk in
TBST. Secondary HRP-conjugated anti-mouse antibody diluted 1:10,000 in TBST was
applied for 1 hour at room temperature. Pico ECL substrate (Pierce) was used to
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develop signal and expose film.

Generation of polyacrylamide gels

Glass coverslips (18-50 mm diameter) were activated by sequential incubation
with 0.2 N HCl, 0.1 M NaOH, 0.5% 3-aminopropyl trimethoxysilane–tetramethoxysilane
(APTMS), and 0.5% glutaraldehyde in PBS. Polyacrylamide gels were made as described
in (Pelham and Wang, 1997), and varying amounts of bis-acrylamide (final concentration
ranging from 0.01 to 0.3% to a mixture of 7.5% acrylamide) were used to generate gels
with shear moduli of 0.4 kPa, 1 kPa, 2.5 kPa, or 12 kPa. Final gel thickness after
polymerization was at least 100 µm. The polyacrylamide surface was prepared for crosslinking by two cycles of UV light-activation of Sulfo-SANPAH (Thermo Scientific), and
pFN and cFN (0.1 mg/ml) were cross-linked to the gel surface by overnight incubation at
4°C. Residual sites were blocked with ethanolamine, and gels were washed and
equilibrated with cell culture media and stored at 37° C until the time of cell plating (later
in the day).

Primary portal fibroblast isolation and culture

Portal fibroblasts were isolated as described in (Li et al., 2007). Briefly, rat livers
were perfused in situ with 300 mg/L collagenase (Worthington), after which the hepatic
hila were removed manually from dissociated parenchymal elements and digested serially
with a 0.033% pronase (Roche) and 0.036% hyaluronidase (Sigma) solution. Cell
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suspensions were filtered through a 30 µm-pore mesh (Sefar America, Inc.). Portal
fibroblasts were cultured in Dulbecco’s modified medium/F-12 (DMEM/F12) with 10%
FBS (Gemini) and 1% penicillin-streptomycin (Gibco).

Immunofluorescence microscopy for cells on gels

Portal fibroblasts were cultured on 12 kPa polyacrylamide supports in regular
growth media as described above for 3 days. From day 3-10, they were cultured in
DMEM/F12 with 3% FBS and 1% penicillin-streptomycin along with 100 pM TGF-β1
(R&D Systems) or 100 nM of TGF-β R1 inhibitor (Calbiochem) or vehicle control (4
mM HCl or DMSO, respectively). On day 10, they were fixed in 4% paraformaldehyde,
permeabilized with 0.1% TritonX-100, and stained with primary αSMA (1:1,000)
antibody overnight at 4° C. Cy3-conjugated donkey anti-mouse IgG2a (1:200, Jackson
Immunoblabs) was applied for 30 minutes at 37°C, and cells were stained with DAPI for
10 minutes. Gels were mounted upside down on glass slides using Fluorescence
Mounting Media (KPL). Images were taken using IP lab software, a CCD camera, and a
Nikon E600 microscope.

Confocal Microscopy

Stellate cells cultured on 12 kPa polyacrylamide supports were fixed,
permeabilized, and incubated with primary antibody as described above for portal
firoblasts. Primary antibodies used were αSMA (1:1,000), vinculin (1:500) and
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phospho-paxillin (1:100). Secondary antibodies were Cy2-conjugated donkey anti-mouse
IgG2a, Cy3-conjugated donkey anti-rabbit, and Cy5-conjugated donkey anti-mouse IgG1
(1:200, Jackson Immunolabs). Images of stained stellate cells were obtained using a Zeiss
LSM-510 Meta confocal microscope and processed with LSM Image Browser.

Primary hepatic stellate cell isolation and culture

Primary hepatic stellate cells were isolated from male retired breeder SpragueDawley rats (weight 550-900 g) as previously described (Liu et al., 2003). Briefly, livers
were perfused in situ and sequentially digested with pronase (Roche) and collagenase
(Worthington). Ex vivo, liver slurries were further digested with DNase (Sigma). Hepatic
stellate cells were separated on a 9% HistoDenz (Sigma) density gradient. Populations
obtained were >95% pure as defined by the presence of lipid droplets. Primary cells were
cultured on uncoated tissue culture treated polystyrene plates or on 0.4-12 kPa shear
modulus polyacrylamide gels coated with a saturating concentration of 0.1 mg/ml pFN or
cFN (Sigma) in M199 media (Invitrogen) supplemented with 10% FBS (Gemini), 2%
penicillin/streptomycin and 1% Fungizone.

Time-lapse microscopy

Phase contrast images were taken at 10-minute intervals for a 6 h period on a
Nikon TE300 inverted microscope (Nikon Instruments, Inc.) in a custom incubation
chamber. Video files were assembled and analyzed with Image-Pro Plus software
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(Media Cybernetics, Inc.). For quantification of area, perimeter, and circularity, cells
were traced in every 4th frame (at 40 minute intervals), and these parameters were
calculated using NIH ImageJ.

Transwell chemotaxis assays

Hepatic stellate cells were cultured for 6 days to allow myofibroblast
differentiation, then starved overnight in media with 0.5% serum. Cells were removed by
trypsin and plated in 0.5% serum containing media in the upper chamber of 8.0 µm pore
FluroBlok transwell inserts (BD Bioscience) coated with 0.02 mg/ml pFN or cFN on both
sides. Cells were incubated at 37°C for 19 h, then stained with 2 µg/ml calcein AM
(Invitrogen, Molecular Probes) for 1 h at 37°C. Fluorescence intensity from the bottom
side of the insert was measured using a microplate reader (BioTek Synergy 2) and
corrected for background fluorescence. Results were normalized to fluorescence
measured on an uncoated insert. For some experiments hepatic stellate cells were also
visualized on an inverted microscope (model DM IRB; Leica Microsystems) with images
taken using a CoolSNAP camera and analyzed using iVision software. Each experiment
used 3-5 replicates per condition.
In experiments with blocking antibodies against integrins or fibronectin, cells or
the FN-coated inserts were pre-treated with antibody for 30 min at 37°C. All antibodies
were used at a 1:50 dilution in PBS with 1% BSA. In experiments with growth factor
treated cells, growth factors and/or inhibitors were added to the top chamber or bottom
chamber of the transwell insert (as indicated in the figure legends) simultaneously with
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the addition of the cells themselves.

ELISA for PDGF-BB

Hepatic stellate cells were cultured in regular growth media for 7 days on pFNcoated or cFN-coated tissue culture plastic. Conditioned media was collected at day 1, 4
and 7. Rat PDGF-BB was measured using a kit (R&D) according to the manufacturer’s
instructions. Recombinant PDGF-BB served as a positive control and was also used to
generate a standard curve.

Western immunoblotting for cellular proteins

Stellate cells were removed from hydrogels with trypsin and lysed in total lysis
buffer (0.15 M NaCl, 0.5 M EDTA pH 8.0, 1% Triton-X 100, 10 mM Tris HCl pH 7.4)
supplemented with Complete protease inhibitor (Roche), 0.1% SDS, 100 nM PMSF, and
0.5% deoxycholic acid. Peptidylprolyl isomerase B (1:10,000, Thermo Scientific) was
used as a loading control. IRDye infrared fluorophore conjugated secondary antibodies
were purchased from Li-Cor. Membranes were visualized using the Odyssey Infrared
Imaging System (Li-Cor). Antibodies used were against α9 (1:10,000), α5 (1:1,000), αv
(1:500), and αSMA (1:10,000).

Integrin knockdown
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shRNAs targeting integrin subunits α9, αv, and α5 were cloned into adenoviral
vectors using the BLOCK-iT U6 RNAi Entry Vector Kit and BLOCK-iT Adenoviral
RNAi Expression System (Invitrogen). Sequences were designed to target both mouse
and rat, but not human, integrins. Virus was made in 293A packaging cells, amplified,
and titered using a plaque forming assay. An MOI of 25, which demonstrated no cell
toxicity, was used for all experiments. shRNA sequences are listed in Table 2-6.

Spinning disc

Hepatic stellate cells were cultured on uncoated tissue culture treated plastic for 7
days, then removed with trypsin and replated on glass coverslips coated with 0.02 mg/ml
pFN or cFN (a saturating concentration). Coverslips were spun at 4000-5000 rpm for 5
minutes. Following the spin, cells were fixed with 3.7% formaldehyde, permeabilized
with triton X-100, and stained with 4',6-diamidino-2-phenylindole (DAPI). Cells were
visualized microscopically and counted in 64 frames. τ50 was calculated using SigmaPlot
(Systat Software, Inc.) and an algorithm developed by Dr. David Boettiger. A detailed
description of the spinning disc protocol is provided here (Boettiger, 2007).

Statistical Analysis

All statistics were performed using GraphPad Prism software. Student’s t-test was used
when only 2 groups were compared; a paired t-test was used when appropriate, as
indicated in figure legends. When 3 or more groups were compared, one-way ANOVA
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Integrin

Sequence 5’  3’

Itga5

GCAGATCTCGGAGTCCTATTACGAATAATAGGACTCCGAGATCTGC

Itgav

GGCTTGAATTCGGTGCCATCTCGAAAGATGGCACCGAATTCAAGCC

Itga9

GGACGCATCCAACTTCATTCACGAATGAATGAAGTTGGATGCGTCC

Scramble

GCATATTCACGAGTATGTGCCCGAAGGCACATACTCGTGAATATGC

Table 2-6. Sequences used for knocking down integrins. 3 sequences were tried per
integrin, and the most effective for each is shown.
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with Bonferroni’s post test was used. Error bars in figures represent SEM from a
minimum of 3 experiments, unless otherwise noted.

Cloning and expression of fibronectin isoforms

A full-length rat fibronectin cDNA containing the EIIIA, EIIIB, and IIICS
domains in the pLen plasmid was provided as a kind gift by Dr. Pam Norton of Drexel
University. Small portions of fibronectin flanking the EIIIA and EIIIB regions, but
lacking the actual domains, were cloned into a donor plasmid by GenScript. These
portions were then cloned into the full length FN using a restriction enzyme and ligation
strategy, to effectively “knockout” the EIIIA and EIIIB domains. Thus all 4 EIIIA/EIIIB
FN isoform combinations were generated in the pLen plasmid. All isoforms still contain
the IIICS domain.
Each isoform was then cloned into a pcDNA3.1 plasmid using TA cloning
technology (Invitrogen). This plasmid features a C-terminal V5 epitope tag and a 6XHis
tag to aid in FN detection and purification. After cloning into both the pLen plasmid and
the pcDNA3.1 plasmid, the entire full length FN sequence was verified to confirm that no
new mutations were introduced. One base differed from the reference sequence in every
clone, and this was corrected by a site directed mutagenesis kit (Stratagene).
The pcDNA3.1 plasmid also contains a neomycin resistance cassette for the
creation of stable cell lines. CHO-K1 cells were transfected with each isoform and
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cultured in 400 ug/ml G418, a dose that killed 100% of untransfected cells, to select for
transfected clones. Resulting clones were pooled and frozen. A control cell line
expressing β-galactosidase in the same construct was also created. Each cell line was
verified to express the appropriate FN isoform by qRT-PCR. Rat total fibronectin mRNA
was essentially undetectable in the lacZ expressing cell line, as expected (Figure 2-1A,
left). In contrast, EIIIA and EIIIB appeared to be present even in the cell lines that should
not have them, albeit at a much lower level than in the appropriate cell lines (Figure 21A, middle and right panels). Presumably, this is because CHO cells express some low
level of endogenous fibronectin and there is a high degree of homology between rat and
hamster EIIIA and EIIIB, allowing it to be detected.
Three of the five cell lines were also verified by Western immunoblotting (Figure
2-1B) by collecting whole cell lysate, proteins adsorbed to the cell surface, and
conditioned media, as described in detail in Current Protocols in Cell Biology (Akiyama,
2001). As expected, β-galactosidase was expressed predominantly in the whole cell
lysate. Fibronectin was detected both in a cell surface adsorbed form as well as in a
soluble form in conditioned media. In both of these fractions, FN ran as both a dimer and
a larger multimer, with the dimer predominating in the conditioned media and the
multimer predominating on the cell surface. The distribution did not appear to be affected
by the presence of EIIIA and EIIIB. Work to purify recombinant fibronectin from these
cell lines is ongoing.
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Figure 2-1. Verification of stable cell lines. A. qRT-PCR for rat fibronectin (total) or
EIIIA+ cFN or EIIIB+ cFN in stable cell lines. The “0” cell line expresses FN that lacks
both EIIIA and EIIIB. B. Growing CHO-K1 stable cell lines were switched to serum
free media. 48 hours later, 3 cellular fractions were collected: total cell lysate, proteins
adsorbed on the cell surface, and soluble proteins in conditioned media. Western
immunoblotting was performed on each fraction using an antibody against the V5 tag. !
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Chapter 3:
Are EIIIA-/- mice protected from liver fibrosis?

Introduction

In vivo, EIIIA+ cFN has been shown to be upregulated in a bile duct ligation
model of liver fibrosis (Jarnagin et al., 1994). However, expression of EIIIA+ cFN has
not been examined in other commonly used models, and it is unclear whether EIIIA+
cFN plays a causative role in the pathogenesis of liver fibrosis or whether it is simply a
marker of liver injury. We sought to determine whether EIIIA-/- mice were protected from
liver fibrosis using two different models: thioacetamide and bile duct ligation.
Thioacetamide is a hepatotoxin and carcinogen. Its exact mechanism of injury is
unknown, but it may induce liver damage by way of reactive oxygen species, after it is
metabolized to acetamide and thioacetamide S-oxide, which is in turn metabolized to
sulfene (Weiler-Normann et al., 2007). It is a model of parenchymal fibrosis, in which the
initial injury occurs in the hepatic sinusoid. Specifically, it induces loss of fenestration of
sinusoidal capillaries as well as formation of a basement membrane like matrix in the
Space of Disse (Mori et al., 1993; Muller et al., 1988; Zimmermann et al., 1987).
Advantages of the thioacetamide model include that it is well tolerated and reproducible;
one practical disadvantage is that fibrosis is slow to develop, requiring a minimum of 12
weeks of thioacetamide administration.
Bile duct ligation is a surgical model of cholestatic liver disease, in which the
common bile duct is ligated, preventing outflow of bile to the duodenum (Accatino et
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al., 1979). It is a model of biliary liver fibrosis, such as that which occurs in biliary
atresia, primary schlerosing cholangitis, or primary biliary cirrhosis. As with
thioacetamide, injury may be due partly to accumulation of reactive oxygen species, but
in this case by way of hydrophobic bile acids rather than an exogenous chemical (Reinehr
et al., 2005). Whereas thioacetamide induces a sinusoidal injury, bile duct ligation affects
the periportal region of the liver, and proliferation of both biliary epithelial cells and
hepatocytes is a prominent feature of this model. Advantages of bile duct ligation are that
fibrosis develops rapidly; disadvantages include greater variability of response between
animals as well as between liver lobes of a given animal, as well as high mortality.
Additionally, the cholangiocyte response seen is not entirely typical of the human
diseases that bile duct ligation is intended to model.

Results

Male EIIIA-/- mice are protected from thioacetamide-induced liver fibrosis

To determine whether EIIIA is required for liver fibrosis, we induced fibrosis in
EIIIA-/- mice, along with heterozygous and wild type littermates, by treatment with
thioacetamide for 12 weeks. As expected, wild type mice upregulated EIIIA+ cFN in
response to thioacetamide (Figure 3-1A), although total fibronectin and EIIIB+ cFN
levels were surprisingly constant (Figure 3-1B). As part of the injury response to
thioacetamide, mice lose weight and their livers increase in size, resulting in an increased
liver weight to body weight ratio. This ratio was increased by thioacetamide in mice of
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Figure 3-1. EIIIA-/- and wild type mice develop similar liver injury after 12 weeks
of thioacetamide (TAA). Mice were administered 200 mg/L TAA in their drinking
water for 12 weeks. n = 12 H2O treated control mice of mixed genotype with respect to
EIIIA, 9 EIIIA-/- mice, 21 heterozygotes, and 9 wild type mice. A-B. The EIIIA and EIIIB
fibronectin splice variants and total fibronectin (Fn1) were measured by qRT-PCR. C.
Liver weight as a percentage of total body weight was measured. D. Serum ALT
activity (U/L) was measured. E. Liver sections were stained with hematoxylin and
eosin (H&E). Scale bar = 50 !m. Statistical significance was performed by one way
ANOVA with Bonferroni"s post test. * = p # 0.05. ** = p # 0.01, *** = p # 0.005.$
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every genotype, and although wild type mice demonstrated the greatest increase, the
difference between wild type and EIIIA-/- mice was not statistically significant (Figure 31C). Thioacetamide treatment also led to very modest increases in serum alanine
aminotransferase (ALT) activity, an indicator of hepatocyte necrosis (Figure 3-1D), and
EIIIA-/- mice and wild type mice had similar levels of hepatocyte necrosis as seen by
H&E staining (Figure 3-1E). These data suggest that EIIIA does not dramatically affect
the degree of liver injury experienced due to thioacetamide.
In addition to achieving a similar level of liver injury, EIIIA-/- mice and wild type
mice developed comparable numbers of myofibroblasts, as demonstrated by staining for
the quintessential myofibroblast marker, αSMA (Figure 3-2A). Additionally, EIIIA-/mice and wild type mice expressed similar levels of αSMA and Timp-1 transcripts
(Figure 3-2B, C). However, a third myofibroblast marker, vimentin, was upregulated only
in wild type mice (Figure 3-3A), as was TGF-β1 (Figure 3-3B), suggesting a potential
uncoupling of TGF-β1 from myofibroblast differentiation.
Interestingly, we found that male, but not female EIIIA-/- mice were protected
from thioacetamide-induced fibrosis. Compared to male wild type littermates, male
EIIIA-/- mice had a lower average fibrosis score (Figure 3-4A), reduced hydroxyproline
deposition (Figure 3-4B), lower expression of fibrillar collagens (Figure 3-4C, D), and
less sirius red staining (Figure 3-4E, top panel). In sharp contrast, compared to female
wild type littermates, female EIIIA-/- mice had comparable or even worse fibrosis by all
parameters measured (Figure 3-4). Importantly, wild type females and wild type males
developed similar degrees of fibrosis (Figure 3-4). Additionally, analysis of the liver
injury and myofibroblast differentiation data (Figures 3-1 to 3-3) indicated that there
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Figure 3-2. EIIIA-/- mice and wild type mice develop equivalent numbers of
myofibroblasts after 12 weeks of thioacetamide treatment. Mice were
administered 200 mg/L TAA in their drinking water for 12 weeks. n = 12 H2O treated
control mice (mixed genotype), 9 EIIIA-/- mice, 21 heterozygotes, and 9 wild type mice.
A. Liver sections were stained for !SMA (brown) and counterstained with hematoxylin
(blue). Scale bar = 100 "m. B. Myofibroblast markers were measured by qRT-PCR
and normalized to expression of glyceraldehyde-3-phosphate dehydrogenase (Gapdh)
and beta 2 microblobulin (B2M). Acta2 = !SMA and Timp1 = TIMP-1. ** = p # 0.01.$
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Figure 3-3. EIIIA-/- mice have decreased vimentin and TGF-!1. Mice were
administered 200 mg/L TAA in their drinking water for 12 weeks. n = 12 H2O treated
control mice (mixed genotype), 9 EIIIA-/- mice, 21 heterozygotes, and 9 wild type mice.
Myofibroblast markers were measured by qRT-PCR and normalized to expression of
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and beta 2 microblobulin (B2M).
A. vim = vimentin. B. tgfb1 = TGF-!1. * = p " 0.05. ** = p " 0.01. *** = p " 0.005.#
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Figure 3-4. Male, but not female, EIIIA-/- mice are protected from early
thioacetamide-induced fibrosis. Mice were administered 200 mg/L TAA in their
drinking water for 12 weeks. n = 6 male and 6 female H2O control mice, 6 male and 3
female EIIIA-/- mice, and 4 male and 5 female wild type mice. A. Fibrosis was scored
by a blinded observer on a scale of 0-4 (0 = normal, 4 = cirrhosis). B. Hydroxyproline
content was assayed biochemically. C-D. Extracellular matrix transcript levels were
measured by qRT-PCR. Col1a2 = collagen I, Col3a1 = collagen III. E. Liver sections
were stained with sirius red. Statistical significance was performed by one way
ANOVA with Bonferroni!s post test. *** = p " 0.005, significant compared to H2O
control and EIIIA-/-.#
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were no gender-related differences in liver injury or αSMA expression (data not shown).
That is, the lack of difference between EIIIA-/- mice and wild type mice in these
parameters was true for both male and female mice.
Twelve weeks of thioacetamide exposure induced only moderate fibrosis in wild
type mice, with an average fibrosis score of 2.4 on a scale of 0 to 4. To investigate
whether development of fibrosis in EIIIA-/- mice was delayed but would eventually reach
the same levels as in wild type mice, we administered thioacetamide for an additional 4
weeks. After 16 weeks of treatment, EIIIA was more highly upregulated than it was at 12
weeks (compare scale of Figure 3-5A to Figure 3-1A), and total fibronectin and EIIIB
were modestly upregulated (Figure 3-5B). EIIIA-/- and wild type mice had a comparable
liver weight to total body weight ratio (Figure 3-5C), and they had similar levels of ALT
activity (Figure 3-5D), similar to results seen at the earlier time point. Additionally,
compared to wild type littermates, EIIIA-/- mice still had similar expression of αSMA
(Figure 3-6A). However, unlike after 12 weeks of thioacetamide, after 16 weeks of
thioacetamide, EIIIA-/- mice had lower expression of Timp-1 than wild type mice (Figure
3-6B), possibly because of a greater upregulation of Timp-1 by wild type mice at 16
weeks than 12 weeks (compare Figure 3-6B to Figure 3-2C). EIIIA-/- mice also had
reduced expression of vimentin and TGF-β1 (Figure 3-6C, D), similar to the results
obtained after only 12 weeks of thioacetamide.
As seen after 12 weeks of thioacetamide, after 16 weeks of thioacetamide, male
EIIIA-/- mice still remained largely protected from fibrosis, as measured by fibrosis score
(Figure 3-7A), and expression of fibrillar collagens (Figure 3-7C, D), although they did
not have reduced hydroxyproline deposition (Figure 3-7B). Female EIIIA-/- mice were
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Figure 3-5: EIIIA-/- and wild type mice develop similar liver injury after 16 weeks
of thioacetamide (TAA). Mice were administered 200 mg/L TAA in their drinking water
for 16 weeks. n = 11 H2O treated control mice of mixed genotype with respect to EIIIA,
7 EIIIA-/- mice, 19 heterozygotes, and 9 wild type mice. A-B. The EIIIA fibronectin
splice variant and total fibronectin (Fn1) were measured by qRT-PCR. C. Liver weight
as a percentage of total body weight was measured. D. Serum ALT activity (U/L) was
measured. E. Liver sections were stained with hematoxylin and eosin (H&E). Scale bar
= 50 !m. Statistical significance was performed by one way ANOVA with Bonferroni"s
post test. * = p # 0.05. ** = p # 0.01, *** = p # 0.005.$
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Figure 3-6: EIIIA-/- mice and wild type mice have similar numbers of
myofibroblasts after prolonged thioacetamide-induced fibrosis. Mice were
administered 200 mg/L TAA for 16 weeks. n = 11 H2O treated control mice of mixed
genotype with respect to EIIIA, 7 EIIIA-/- mice, 19 heterozygotes, and 9 wild type mice.
Myofibroblast markers were measured by qRT-PCR and normalized to expression of
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and beta 2 microglobulin (B2M).
A. Acta2 = !SMA. B. Timp1 = TIMP-1. C. Vim = vimentin. D. Tgfb1 = TGF-"1.
Statistical significance was performed by one way ANOVA with Bonferroni#s post test. *
= p $ 0.05. ** = p $ 0.01.%
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Figure 3-7: Male EIIIA-/- remain protected from prolonged thioacetamide-induced
fibrosis. Mice were administered 200 mg/L TAA for either 16 weeks. n = 7 male and 4
female H2O control mice, 4 male and 3 female EIIIA-/- mice, and 3 male and 6 female
wild type mice. A. Fibrosis was scored by a blinded observer on a scale of 0 (normal)
to 4 (cirrhosis). B. Hydroxyproline content was measured biochemically. C-D.
Extracellular matrix transcripts were measured by qRT-PCR. Col1a2 = collagen I and
Col3a1 = collagen III. Statistical significance was performed by one way ANOVA with
Bonferroni!s post test. * = p " 0.05. ** = p " 0.01.#
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again not protected (Figure 3-7). Despite extending thioacetamide treatment to 16 weeks,
the majority of wild type mice were still only fibrotic, rather than cirrhotic, with a mean
fibrosis score of 2.9 (compared to 2.4 at 12 weeks). Nonetheless, these data strengthen
those of the twelve week time point and demonstrate that male EIIIA-/- mice are protected
from both mild-to-moderate and moderate-to-severe fibrosis.

EIIIA-/- mice are not protected from bile duct ligation induced fibrosis

Thioacetamide is a hepatotoxic agent, and it induces a parenchymal pattern of
liver injury in which abnormal extracellular matrix is deposited along the liver sinusoids,
where hepatic stellate cells reside in the normal liver. In order to determine whether
EIIIA is required for biliary fibrosis, we subjected EIIIA-/- and wild type littermate mice
to ligation of the common bile duct for 14 days, with sham-operated animals serving as
negative controls.
Similar to the results in the thioacetamide model, both EIIIA-/- mice and wild type
mice developed an increased liver weight to body weight ratio (Figure 3-8A). However,
whereas the mice that received thioacetamide developed only modestly elevated ALT
activity regardless of genotype, ALT activity in mice that underwent bile duct ligation
was more markedly elevated, and there appeared to be a correlation between serum ALT
activity and genotype (Figure 3-8B).
EIIIA-/- and wild type mice demonstrated equivalent expression of several
myofibroblast markers after bile duct ligation (Figure 3-8, C-D), and they developed
similar degrees of fibrosis, as measured by sirius red staining (Figure 3-9, A-B),
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Figure 3-8: EIIIA-/- mice and wild type mice develop equivalent injury and
myofibroblast numbers after bile duct ligation. Mice underwent bile duct ligation
and were euthanized 14 days post-operation. Depending on the experiment, n =
between 6-10 control (sham operated) animals of mixed genotype, 5 EIIIA-/- mice, and
6 wild type mice. A. Percent liver weight to total body weight. B. Serum ALT activity (U/
L). C. Myofibroblast markers were measured by qRT-PCR and normalized to
expression of 18s ribosomal RNA and glucuronidase B (Gusb). Acta2 = !SMA, Timp1
= TIMP-1, Vim = vimentin, Pdgfrb = PDGFR", and Tgfb1 = TGF-"1. D. !SMA staining
(not shown) was quantified using Adobe Photoshop. #
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fibrosis score (Figure 3-9C), hydroxyproline content (Figure 3-9D), and expression of
fibrillar collagens (Figure 3-9E). There was a modest increase in EIIIB+ cFN (but not
total fibronectin) in both EIIIA-/- and wild type mice in the bile duct ligation model
(Figure 3-9F). Importantly, although the cohort of animals used was small, there were no
obvious gender-related differences in susceptibility of EIIIA-/- mice or wild type mice to
bile duct ligation induced fibrosis (data not shown).
To determine whether EIIIA-/- mice might be protected from bile duct ligationinduced fibrosis at an earlier time point, we euthanized mice 4-6 days after bile duct
ligation. At this early time point, neither EIIIA-/- mice or wild type mice had developed
an increased liver weight to body weight ratio (Figure 3-10A). For every myofibroblast or
fibrosis parameter tested there was no difference between EIIIA-/- mice and wild type
mice; either the markers were not yet upregulated compared to sham operated controls, or
else they were upregulated to an equal extent by EIIIA-/- mice and wild type mice (Figure
3-10B-D). These data suggest that the lack of protection from fibrosis in the EIIIA-/- mice
is not an issue of gender or timing but instead inherent to the bile duct ligation model.
It was not possible to examine time points after 14 days, as some mice begin to
develop signs of end stage liver disease, such as ascites, (Figure 3-11A, Table 2-4) and
mortality was too high (Figure 3-11B). Surprisingly, while only a few mice developed
ascites, those that did were either heterozygous for EIIIA (4 mice, Figure 3-11C) or wild
type mice that had only a modest upregulation of EIIIA (1 mouse, Figure 3-11D). This
suggests a potential correlation between development of ascites and an intermediate
EIIIA expression level, although the data set is too small to perform statistical analysis to
determine if this is significant.
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Figure 3-9: EIIIA-/- mice and wild type mice develop equivalent fibrosis after bile
duct ligation. Mice underwent bile duct ligation and were euthanized 14 days postoperation. Depending on the experiment, n = between 4-10 control (sham operated)
animals of mixed genotype, 5 EIIIA-/- mice, and 6 wild type mice. A. Liver sections
were stained with sirius red. Scale bar = 100 !m. B. Sirius red staining was quantified
using Adobe Photoshop. C. Fibrosis was scored by a blinded observer on a scale of 0
(normal) to 4 (cirrhosis). D. Hydroxyproline content (!g) was quantified. E-F.
Extracellular matrix transcript levels were measured by qRT-PCR. Col1a2 = collagen I,
Col3a1 = collagen III, Fn1 = fibronectin, EIIIB = EIIIB+ cFN, and EIIIA = EIIIA+ cFn.
Statistical significance was performed by one way ANOVA with Bonferroni"s post test. *
= p # 0.05. ** = p # 0.01, *** = p # 0.005.$
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Figure 3-10: EIIIA-/- mice are not protected from bile duct ligation-induced
fibrosis, even at early time points. Mice were euthanized 4-6 days after undergoing
ligation of the common bile duct or a sham operation. n = 4 sham operated animals of
mixed genotype, 5 EIIIA-/- mice, 3 heterozygotes, and 6 wild type mice. A. Liver weight
as a percentage of total body weight. B. Myofibroblast transcripts were measured by
qRT-PCR. Results are normalized to expression of the 18s ribosomal rRNA gene as
well as glucluronidase B (Gusb). C. Expression of fibrillar collagen transcripts was
measured by qRT-PCR. D. Expression of total fibronectin and fibronectin splice
variants was measured by qRT-PCR. E. Fibrosis was scored by a blinded observer. * =
p ! 0.05.!
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Figure 3-11: Morbidity and mortality after bile duct ligation. EIIIA-/- or wild
type mice were euthanized 2 weeks after undergoing ligation of the common bile
duct or a sham operation. A. Some mice developed ascites (right). B. Mortality
was independent of genotype. C. Number of mice per genotype group that
developed ascites. D. Mice that developed ascites had an intermediate level of
EIIIA expression. Each circle or star represents an individual mouse. !
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Discussion

Although EIIIA+ cFN was upregulated by wild type mice in both the
thioacetamide and the bile duct ligation model of liver fibrosis, EIIIA-/- mice were
protected only from thioacetamide-induced fibrosis, and even then, only males were
protected. By using two time points per model, we demonstrated that the difference in
susceptibility was due to an inherent difference in the models used, rather than simply an
issue of timing; i.e. male EIIIA-/- mice were protected from mild to moderate fibrosis
following 12 weeks of thioacetamide administration but not from 6 days of bile duct
ligation, and they were protected from moderate to severe fibrosis following 16 weeks of
thioacetamide administration but not from 2 weeks of bile duct ligation. Interestingly,
female EIIIA-/- mice are not protected from thioacetamide-induced fibrosis at either time
point; the reason for this is unknown. Additionally, EIIIA did not appear to be required
for expression of αSMA in either model of fibrosis. We explore the mechanism for this
surprising finding in chapter 4.
It is perhaps unsurprising that the thioacetamide and bile duct ligation models of
liver fibrosis yielded different results with respect to the requirement for EIIIA+ cFN, as
they model two very different human disease processes. In addition to the fact that these
processes occur in different microenvironments within the liver and involve different cell
types (the subject of chapter 4 of this thesis), there may be differences in ECM expression
between these two models. Although EIIIB levels were not elevated until later time
points in both models of fibrosis, the work of another lab member, Maryna Perepelyuk,
has revealed that portal fibroblasts isolated from livers of rats that have undergone bile
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duct ligation express high levels of EIIIB (data not shown). Thus, it is possible that the
EIIIB splice variant of cFN may compensate for the lack of EIIIA in biliary fibrosis.
While susceptibility to fibrosis has never been studied directly in EIIIB-/- mice,
fibroblasts derived from those mice have impaired matrix assembly in vitro (Fukuda et
al., 2002), making EIIIB an attractive target for future study.
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Chapter 4:
EIIIA is dispensable for myofibroblast differentiation but promotes stellate cell motility

Introduction

Although myofibroblasts are considered to be a discrete cell type, they
differentiate from a wide variety of precursor cells. In the liver alone, myofibroblasts
have been suggested to derive from hepatic stellate cells, portal fibroblasts, resident or
bone-marrow derived hematopoietic cells, and even epithelial cells such as hepatocytes
and cholangiocytes. We hypothesized that the disparate results between the thoacetamide
and bile duct ligation models of liver fibrosis might be explained by differences in the
relative contributions of myofibroblast populations and their requirement or lack of
requirement for EIIIA. Specifically, we suspected that EIIIA+ cFN would be required for
some myofibroblast function of hepatic stellate cells, e.g. contraction, motility, ECM
secretion, or proliferation, but not of portal fibroblasts.

Results

Portal fibroblasts are the dominant myofibroblast precursors in biliary fibrosis

Although hepatic stellate cells are well-established as the predominant source of
extracellular matrix in fibrosis of the hepatic parenchyma, several groups have reported
that portal mesenchymal cells, including portal fibroblasts, are more important
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contributors than hepatic stellate cells to the myofibroblast population in biliary fibrosis
(Tang et al., 1994; Tuchweber et al., 1996; Kinnman et al., 2003; Beaussier et al., 2007).
In agreement with these reports, we found that, while there were many αSMA-expressing
myofibroblasts in the portal region at day 6 following bile duct ligation (Figure 4-1A),
there were few hepatic stellate cells (as determined by staining for desmin) (Figure 4-1B).
Instead, stellate cells were found along the liver sinusoids, where they reside in the
healthy liver. Thus, portal myofibroblasts are more likely to be derived from portal
fibroblasts and other portal mesenchymal cells than from hepatic stellate cells. As would
be expected if portal fibroblasts played a greater role in biliary than in parenchymal
fibrosis, elastin, a previously identified portal fibroblast marker (Li et al., 2007), was
more highly upregulated in the bile duct ligation model than in the thioacetamide model
(Figure 4-1C). Additionally, we found no difference in elastin expression or in the
number of elastin-expressing cells in portal areas between EIIIA-/- mice and wild type
mice (Figure 4-1, C-D).

Neither portal fibroblasts nor hepatic stellate cells require EIIIA for myofibroblast
differentiation

We wondered if EIIIA+ cFN might be required for myofibroblast behavior of
hepatic stellate cells, but not portal fibroblasts. To address this question, we used an in
vitro culture system in which primary cells are cultured on polyacrylamide hydrogels
with defined shear moduli (stiffnesses) that mimic the mechanical environment of the
normal (soft, average 0.5 kPa) or injured (stiff, 1-22 kPa) liver (Georges et al., 2007).
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Figure 4-1: !SMA-expressing cells in the portal scar are portal fibroblasts. A.
!SMA staining (brown) from wild type mice 6 days post bile duct ligation. B. Desmin
staining in livers of wild type mice 6 days post bile duct ligation. Portal area is outlined
in red (right panel). Scale bar = 50 "m. C. Elastin (Eln) expression was measured by
qRT-PCR in wild type or EIIIA-/- mice 2 weeks after bile duct ligation (BDL) or after 16
weeks of thioacetamide (TAA) treatment. D. Liver sections from day 6 post bile duct
ligation were stained for elastin (brown) and with hematoxylin (blue). Scale bar = 50
"m. "
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We have previously demonstrated that expression of αSMA by portal fibroblasts requires
a mechanically stiff substrate as well as transforming growth factor beta 1 (TGFβ-1) (Li
et al., 2007), whereas expression of αSMA by stellate cells to myofibroblasts requires
only the stiff substrate (data not shown).
Primary rat portal fibroblasts or hepatic stellate cells were plated on 12 kPa
polyacrylamide hydrogels coated with commercially available human pFN (which lacks
EIIIA) or cFN (which contains EIIIA) immediately after isolation. We verified that pFN
is EIIIA negative by immunoblotting (Figure 4-2A), and we confirmed that both matrices
were equally crosslinked to the gel (Figure 4-2B).
As expected given our in vivo data, portal fibroblasts differentiated equally well
on pFN-coated and cFN-coated 12 kPa gels, as measured by morphology and staining for
αSMA, with treatment with TGFβ-1 alone or TGFβ-1 along with a TGFβR inhibitor
serving as positive and negative controls, respectively (Figure 4-3A). Similar to portal
fibroblasts, hepatic stellate cells cultured on pFN-coated and cFN-coated gels also
expressed equivalent levels of the myofibroblast marker αSMA (Figure 4-3B) as well as
extracellular matrix genes (Figure 4-3C), suggesting that the presence of EIIIA is not
required for myofibroblast differentiation of either cell type, in accordance with our in
vivo data (chapter 3).
Unpublished data from our lab as well as the work of others (Jarnagin et al., 1994)
has indicated that the principle source of EIIIA+ cFN in the liver is not the
myofibroblasts themselves, but rather sinusoidal endothelial cells. Nonetheless, one
potential explanation for the cells’ ability to differentiate on pFN might be that they are
producing their own EIIIA+ cFN that is able to bind to the pFN-coated gel. To attempt
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Figure 4-2: Only cFN contains EIIIA, and both matrices coat polyacrylamide
gels equally well. A. Purchased pFN and cFN were immunoblotted for total
fibronectin and EIIIA. B. Polyacrylamide supports coated with pFN or cFN were
stained for total fibronectin (green) and EIIIA+ cFN (red). !
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Figure 4-3. EIIIA is not required for myofibroblastic differentiation of portal
fibroblasts or hepatic stellate cells. A. Portal fibroblasts were cultured on 12 kPa
hydrogels coated with pFN or cFN in the presence or absence of TGF-!1 and a TGF!
R1 inhibitor. Phase contrast images were taken and cells were stained for "SMA.
Scale bar = 50 #m. B. Stellate cells were cultured on pFN-coated or cFN-coated gels
for 7 days. qRT-PCR for "SMA (Acta2) on 0.4-12 kPa gels was performed. Error bars
represent SD from 2 experiments. C. qRT-PCR for extracellular matrix genes on 12
kPa gels. Col1a2 = collagen I, Col1a3 = collagen III, Col4a1 = collagen IV, Tnc =
tenascin C, and EIIIB/FN1 = ratio of EIIIB+ cFN to total FN. Error bars represent SEM
from 4 experiments. p values from a paired t-test are indicated.!
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to rule out this possibility, we performed qRT-PCR for EIIIA in portal fibroblast and
stellate cell derived myofibroblasts cultured on tissue culture plastic, and indeed, both
cell populations expressed EIIIA (Figure 4-4A) and EIIIB (Figure 4-4B), at relatively
high levels, with biliary epithelial cells serving as a negative control. To examine this
further, we cultured hepatic stellate cells on pFN-coated and cFN-coated gels and
performed qRT-PCR for total FN or EIIIA+ cFN. Interestingly, stellate cells cultured on
cFN-coated gels actually expressed less fibronectin than those on pFN-coated gels, but of
the fibronectin that was produced, nearly all was EIIIA+, given them a higher ratio of
EIIIA+ isoforms than those cultured on pFN (Figure 4-4C). The fact that stellate cells
cultured on pFN-coated gels produce more total fibronectin was confirmed by
immunofluorescence experiments, in which stellate cells cultured on pFN-coated gels
appeared to be sitting on a bed of fibronectin on top of what was initially present on the
gel, whereas most of the fibronectin that was visualized on the cFN-coated gels appeared
to represent the original cFN-coating (Figure 4-4D). In agreement with the qRT-PCR
data, the FN produced by stellate cells on pFN contained minimal EIIIA (Figure 4-4-E).
Thus, while stellate cells and portal fibroblasts are capable of producing EIIIA+ cFN, it
does not appear to be deposited on the polyacryalmide gels to a significant extent.

Culturing hepatic stellate cells on cFN promotes cell motility

Whereas hepatic stellate cells cultured on pFN displayed a typical myofibroblast
appearance, with an angular shape and prominent αSMA-containing stress fibers, cells
cultured on cFN had more diffuse organization of αSMA (Figure 4-5A) and a more
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Figure 4-4. Hepatic stellate cells do not deposit large amounts of EIIIA+ cFN
on pFN-coated polyacrylamide gels. A-B. Primary hepatic stellate cells (HSC),
portal fibroblasts (PF), or biliary epithelilal cells (BEC) were cultured on regular
tissue culture plastic for 1 week. qRT-PCR for EIIIA+ cFN and EIIIB+ cFN was
performed. C. Hepatic stellate cells were cultured on 12 kPa pFN-coated or cFNcoated polyacrylamide gels, and qRT-PCR for total FN or EIIIA+ cFN was
performed. The ratio of EIIIA+ cFN to total FN is graphed in the third set of bars. D.
Stellate cells were cultured on 12 kPa pFN-coated or cFN-coated gels for 7 days,
then fixed and stained for !SMA (green) or total FN (red in left panel, white in right
panel for easier visualization), and with DAPI (blue). E. Stellate cells were cultured
as in (D) then stained for !SMA (green), EIIIA+ cFN (red), and DAPI (blue). The top
panel of the bisected images on the left is enlarged on the right. !
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elongated cell shape (Figure 4-5B). Staining for the focal adhesion marker vinculin
showed long, mature-appearing focal adhesions in the cells cultured on pFN, whereas
cells on cFN demonstrated punctate focal contacts (Figure 4-5, C-D). These morphologic
attributes are characteristic of motile cells, suggesting that cFN promotes motility rather
than fibrogenesis. The difference in morphology was observed over a range of stiffnesses
that enable stellate cell myofibroblast differentiation (2.5-12 kPa), but there was no
difference between cells cultured on cFN and pFN on 0.4 kPa gels, on which hepatic
stellate cells remain non-myofibroblastic (Figure 4-5E). Cells demonstrated a
myofibroblast morphology on both pFN-coated and cFN-coated tissue culture plastic,
which is orders of magnitude stiffer than even a cirrhotic liver, and this was unaffected by
adding an EIIIA blocking antibody (Figure 4-5E).

EIIIA+ cFN increases hepatic stellate cell motility

To determine whether the difference in cell morphology translated to a functional
difference in motility, we performed time-lapse microscopy. Hepatic stellate cells
cultured on cFN-coated polyacrylamide hydrogels were more dynamic than those
cultured on pFN-coated gels, extending and retracting protrusions as reflected by a
greater average change in cell area and perimeter over time (Figure 4-6, A-B). Cell
circularity was fairly constant on both matrices; that is, the cells on pFN remained spread
out and angular, whereas the cells on cFN remained elongated (Figure 4-6C).
Furthermore, stellate cells cultured on cFN were more motile than those on pFN, even in
the absence of a chemotactic gradient, as measured by nuclear travel (Figure 4-6, D68
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Figure 4-5. Hepatic stellate cells cultured on cFN have motile morphology.
Stellate cells were cultured on pFN-coated or cFN-coated polyacrylamide gels for 7
days. A. Cells on 12 kPa gels stained for !SMA. Scale bar = 20 "m. B. Cell shape
was quantified by measuring cell circularity (circularity = 4#A/P2, where A = cell area
and P = perimeter). N = 18-23 cells per condition from 2 experiments. C. Stellate
cells on 12 kPa gels stained for vinculin. Scale is the same as in D. D. Focal
adhesion length was calculated using NIH ImageJ. N = 125-150 focal adhesions per
cell from 3 representative cells per matrix. E. Stellate cells were stained for !SMA
(red) or with DAPI (blue) or visualized by phase contrast microscopy after treating
with an isotype control antibody or an EIIIA blocking antibody. * = p $ 0.05, *** = p $
0.005. !
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Figure 4-6. Hepatic stellate cells cultured on cFN are more motile. Cells were
cultured on pFN- or cFN-coated 12 kPA gels for 7 days, followed by time-lapse
microscopy performed over 6 hours. A-C. Cells were outlined on still frames taken
at 40 minute intervals. Area, perimeter, and circularity were calculated, and the
average percent change in each parameter from one frame to the next is graphed.
N = 15 cells per matrix. D-E. Nuclear coordinates were traced. Each line represents
the path of an individual cell. N = 15 cells per matrix. F. The average total path
length per cell was calculated. p values were calculated using Student!s t-test. * = p
" 0.05, ** = p " 0.01, *** = p " 0.005.#
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F).
In vivo, stellate cells do not move randomly but rather in response to gradients of
growth factors and cytokines. To model this process, we used transwell chemotaxis
assays and found that cells plated on cFN-coated transwell inserts exhibited greater
chemotaxis toward serum than those plated on pFN-coated inserts (Figure 4-7, A-B). The
increased migration on cFN was attenuated by treatment with two EIIIA blocking
antibodies, IST9 and MAB1940, but not by an unrelated FN-binding antibody (FN C-20),
demonstrating a specific requirement for EIIIA (Figure 4-7C). In contrast, neither culture
on cFN nor treatment with EIIIA blocking antibodies had any effect on motility of portal
fibroblasts (Figure 4-7, D-E).

Discussion

At early time points after bile duct ligation, both EIIIA-/- and wild type mice
have αSMA+ myofibroblasts in portal scars. Staining for portal fibroblast versus stellate
cell markers suggests that these myofibroblasts are derived from portal mesenchymal
cells rather than stellate cells, and it is only later that stellate cell derived myofibroblasts
infiltrate the portal area. Surprisingly, neither portal fibroblasts nor stellate cells have an
absolute requirement for EIIIA for myofibrobastic differentiation. Instead, EIIIA+ cFN
promotes stellate cell motility and chemotaxis.
Although some groups have suggested that EIIIA+ cFN drives myofibroblast
differentiation (Serini et al., 1998; Muro et al., 2008; Jarnagin et al., 1994), we found no
significant difference in expression of extracellular matrix genes or αSMA in hepatic
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Figure 4-7. Hepatic stellate cells cultured on cFN have increased chemotaxis.
A. Stellate cells were plated on transwell inserts coated with pFN or cFN. After 19
hours, cells were stained with calcein a.m. and visualized at 10x magnification. B.
Mean fluorescence intensity was measured. p-values were calculated with a paired
t-test from 8 experiments. C. Transwell inserts were coated with pFN or cFN, then
incubated for 1 h with antibodies before plating cells. Results are averaged from 5
experiments. D. Portal fibroblasts were plated on transwell inserts coated with pFN
or cFN. After 19 hours, cells were stained with calcein a.m., and mean fluorescence
intensity was measured. E. Transwell inserts were coated with pFN or cFN, then
incubated for 1 h with antibodies before plating cells. p values were calculated
using a one-tailed paired t-test. * = p ! 0.05, ** = p ! 0.01, *** = p ! 0.005."
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stellate cells and portal fibroblasts cultured on pFN versus cFN. This may reflect an
important difference in methodology between our work and that of others, in that we
employed a mechanically physiologic cell culture system. The phenotype of both stellate
cells and portal fibroblasts is highly dependent on the mechanical properties of their
surrounding environment (Li et al., 2007), and FN is itself exquisitely mechanosensitive.
Tissue culture plastic and glass have stiffnesses in the GPa range, orders of magnitude
stiffer than even a cirrhotic liver, and FN adherent to these surfaces may be nonphysiologically rigid or adopt abnormal conformations.
In its secreted soluble form (pFN), FN has a compact globular structure, but in its
extracellular matrix-associated form (cFN), FN is assembled into insoluble fibrils in a
process that is thought to involve unfolding of the type III repeats and exposure of cryptic
binding sites (reviewed in (Gao et al., 2006; Mao and Schwarzbauer, 2005)). Splicing in
of EIIIA and EIIIB may stimulate unfolding of FN (Carnemolla et al., 1992; White et al.,
2008) and fibrillogenesis (Fukuda et al., 2002; Abe et al., 2005; Bazigou et al., 2009),
which may promote motility (Rozario et al., 2009). The process of fibrillogenesis is celldriven, integrin-dependent and mechanosensitive, (reviewed in (Mao and Schwarzbauer,
2005)), and there is progressive unfolding and increased rigidity (Young’s modulus) of
FN with increasing substrate stiffness (Antia et al., 2008; Klotzsch et al., 2009). Adhesion
of cells to FN depends on its conformation, which is regulated by the absorptive
chemistry of the underlying substrate, and these different chemistries can have profound
effects on cell behaviors, such as promoting differentiation versus proliferation (Garcia et
al., 1999). Additionally, adhesion is different on native fibronectin matrix than on glassadsorbed FN, nearly independently of stiffness (Engler et al., 2009). Thus, for both
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chemical and mechanical reasons, it is likely that cells cultured on FN-coated plastic or
glass substrates encounter FN in a different conformation than do cells on soft substrates,
and they may be prevented from dynamically interacting with it in a physiologic fashion.
It is of course also possible that our results differ from those of others not because
we used a mechanically physiologic system but simply because cells on pFN are making
their own EIIIA+ cFN. Indeed, we do find a little evidence for this possibility, (Figure 44). To explore this further, we plan to repeat the myofibroblast differentiation
experiments using stellate cells isolated from EIIIA-/- mice. This is not a trivial
undertaking due to the small size of mice, but it is of the utmost importance if we are to
definitely rule out cellular production of EIIIA+ cFN as an artifactual explanation for our
finding that EIIIA+ cFN is not required for myofibroblastic differentiation. Importantly,
even if there is a small amount of stellate cell-derived EIIIA+ cFN deposited on pFNcoated gels, stellate cells on pFN and cFN do not share the same phenotype. That is,
enhanced motility was only observed in stellate cells cultured on cFN-coated gels. This,
along with the fact that an EIIIA blocking antibody had no effect on myofibroblast
morphology when cells were cultured on either pFN-coated or cFN-coated tissue culture
plastic (Figure 4-5E), and the fact that αSMA expression was comparable between EIIIA/-

and wild type mice in two models of fibrosis in vivo, support our conclusions that

myofibroblastic differentiation is independent of EIIIA.
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Chapter 5:
Enhanced motility of hepatic stellate cells on cFN requires EIIIA and α9β1 integrin

Introduction

Cell motility is a complex behavioral process, involving interaction of cellular
surface receptors with the extracellular environment, transmission of information into the
cell through focal adhesions and signaling complexes, and ultimately reorganization of
the cytoskeleton. Much of the work on hepatic stellate cell motility has focused on
soluble chemoattractants. Although chemotaxis can be induced by several growth factors
and chemokines, including TGFβ and EGF (Yang et al., 2003; Chang et al., 2008), MCP1 (Marra et al., 1999), IGF-1 (Gentilini et al., 2000) and CXCR3 ligands (Bonacchi et al.,
2001), PDGF is the most potent known stellate cell chemoattractant (Yang et al., 2003;
Chang et al., 2008; Ikeda et al., 1999; Kinnman et al., 2000; Melton and Yee, 2007).
PDGF-induced stellate cell motility is likely to involve crosstalk with integrin signaling
(Carloni et al., 1997) and focal adhesion disassembly (Melton et al., 2007); a previous
study demonstrated that blockade of αvβ3 using small molecule inhibitors attenuated
PDGF-induced hepatic stellate cell migration (Patsenker et al., 2007).
Having determined that EIIIA+ cFN promotes stellate cell motility, rather than
myofibroblast differentiation, one ongoing goal of this work has been to delineate what is
happening downstream of EIIIA+ cFN to mediate this effect. We have examined
candidate factors at every stage of the motility process, but the bulk of the work has
focused on the potential role of PDGF signaling and integrin signaling in mediating
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motility on cFN. We demonstrate here that cFN does not affect either expression of or
response to PDGF, but instead mediates its motility promoting effects via α9β1 integrin.

Results

cFN does not affect expression of or response to PDGF-BB

Because PDGF-BB is well established as the most robust inducer of hepatic
stellate cell motility, we investigated whether it might be acting synergistically with cFN
to promote chemotaxis. We first examined whether culture on cFN induced changes in
expression of either PDGF-BB or PDGFRβ, the isoforms of the ligand and receptor,
respectively, that have been shown to be most relevant for fibrosis (Pinzani et al., 1991;
Pinzani et al., 1996). There was no difference in PDGF-BB expression as measured by
ELISA between stellate cultured on pFN versus cFN, though it is worth mentioning that
this experiment was done using cells cultured on tissue culture plastic rather than
polyacrylamide gels (Figure 5-1A). Surprisingly, stellate cells cultured on cFN expressed
slightly less PDGFRβ as measured by qRT-PCR (Figure 5-1B), though this difference
was not statistically significant. By Western immunoblot, both total PDGFRβ and
PDGFRβ phosphorylated on Y751 were undetectable in serum-starved cells but were
upregulated by treatment with PDGF-BB, supporting the work of others suggesting an
autocrine loop of PDGF signaling (Figure 5-1C) (Pinzani et al., 1989). PDGF-BB
treatment induced a greater upregulation of phosphorylated and total PDGFRβ in stellate
cells cultured on cFN than in those cultured on pFN, but the fact that concomitantly
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Figure 5-1. Stellate cells cultured on cFN express equivalent levels of PDGFBB and its receptor, PDGFR". A. Stellate cells were cultured on pFN-coated or
cFN-coated tissue culture plastic for 7 days. Secreted PDGF-BB was measured by
ELISA. Results are from a single experiment, and error bars represent SD. B.
Stellate cells were cultured on pFN-coated and cFN-coated 12 kPa polyacrylamide
gels for 7 days. PDGFR! (transcript name PDGFRb) was measured by qRT-PCR.
Results show SEM from 4 independent experiments. C. Stellate cells were cultured
on pFN-coated or cFN-coated gels for 7 days. On day 5, cells were serum starved
overnight. On day 6, cells were treated overnight with vehicle (V), PDGF-BB (P) or
PDGF-BB plus a PDGR! kinase inhibitor, AG1295 (P + I). Peptidylprolyl isomerase
b (Ppib) serves as a loading control.!
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treating with AG1295, an inhibitor of the kinase activity of PDGFRβ that blocks
autophosphorylation at Y751, failed to decrease the signal for phosphorylated PDGFRβ
raises questions about antibody specificity. Thus, at this time we cannot yet draw firm
conclusions as to whether culture on cFN affects PDGFRβ phosphorylation.
It is also possible that there is no difference in expression of PDGF-BB on pFN
versus cFN, but that culture on cFN in some way sensitizes stellate cells to the effects of
PDGF-BB. We treated stellate cells cultured on pFN-coated or cFN-coated 12 kPa
polyacrylamide gels with PDGF-BB and found that it decreased the incorporation of
αSMA into stress fibers, regardless of the extracellular matrix on which cells were
cultured (Figure 5-2A). Additionally, we performed transwell chemotaxis assays in which
PDGF-BB was added to the top, bottom, or both chambers. Regardless of where PDGFBB was added, it increased stellate cell motility on both pFN and cFN, with the largest
effect occurring when it was acting as a chemoattractant in the bottom chamber, rather
than as a general “motogen” in the top chamber (Figure 5-2B). These data do not support
a role for synergy between cFN and PDGF-BB but rather suggest that the motilitypromoting effects of cFN are independent of those of PDGF-BB.

cFN does not affect integrin expression or localization

Although the motility-promoting effects of cFN appear to be independent of
PDGF-BB, another likely candidate pathway for mediating these effects is integrin
signaling. Fibronectins bind to multiple integrins (Pankov and Yamada, 2002), and
integrins play a large role in cell motility (Harburger and Calderwood, 2009). The
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Figure 5-2. PDGF-BB decreases incorporation of !SMA into stress fibers and
increases chemotaxis on both pFN and cFN. A. Hepatic stellate cells were
cultured on 12 kPa pFN-coated or cFN-coated polyacrylamide gels for 7 days,
then fixed and stained for !SMA (green). Cells were visualized by confocal
microscopy. Representative cells are shown. B. Transwell migration experiments
were performed in which PDGF was added to the top, bottom, or both chambers.
Results are averaged from 3 independent experiments of 3 replicates each. Error
bars represent SEM. The average fold increase with PDGF-BB treatment
compared to vehicle for each ECM is indicated in the table on the right. "
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classical FN receptor is α5β1 integrin, which binds to an RGD sequence in the tenth type
III FN repeat, though αvβ3 can also bind here and is often antagonistic to α5β1 with
respect to cell behaviors (Huveneers et al., 2008). Inclusion of EIIIA has been shown to
increase α5β1-mediated adhesion to FN, hypothetically by inducing a conformational
change in FN that leads to increased exposure of the RGD (Manabe et al., 1997).
Additionally, integrins α4β1 and α9β1 have been reported to bind specifically to EIIIA
itself (Liao et al., 2002; Shinde et al., 2008).
Hepatic stellate cells express the FN-binding integrins α5β1 (Zhou et al., 2000)
and αvβ3 (Zhou et al., 2004), but to our knowledge, expression of the EIIIA-binding
integrins α9β1 and α4β1 has not been investigated in these cells. We confirmed expression
of the α5, αv, and α9 (Figure 5-3, A-C) as well as β1 and β3 (data not shown) integrin
subunits on cFN- and pFN-coated hydrogels, but we were unable to detect either protein
or mRNA for the α4 subunit (Figure 5-3, A-C and data not shown).
Culture on cFN versus pFN did not regulate integrin expression level (Figure 53A) or the surface localization of α5β1 (Figure 5-3D). It was not possible to specifically
examine surface localization of α9β1, due to the lack of antibodies to the extracellular
domain. Staining of fixed cells revealed that α5 is associated with vinculin in focal
adhesions and is excluded from lamellipodia, whereas α9 is present diffusely throughout
the cell (Figure 5-3E). This subcellular localization was not affected by pFN or cFN.

α9β1 is required for cFN-enhanced motility of hepatic stellate cells
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Figure 5-3. Integrin expression and
localization are not regulated by
fibronectin. A. Integrin expression was
detected by immunoblotting (left) and
normalized to peptidylprolyl isomerase
/01!2301$
B (Ppib) (4 independent experiments);
(right). B. qRT-PCR on day 7 stellate
cells. Cells express !5, !9, and !v (not
shown), but not !4. C. qRT-PCR for !4
was performed on stellate cells on
stellate cells at day 1-7 after isolation.
/01!2301$
Whole spleen is a positive control.
Results are normalized to expression of
18s rRNA. D. Flow cytometry for !5.
The blue line represents specific
staining, and the red line is a secondary
antibody only control. E. Stellate cells
were stained for !5 or !9 (both red), and
!SMA (green, top panels) or vinculin
(green, bottom panels). !
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To investigate which cFN-binding integrins were responsible for enhanced
hepatic stellate cell motility on cFN, we inhibited the integrins using function blocking
antibodies and shRNAs. Successful knockdown of each integrin subunit was verified by
qRT-PCR (Figure 5-4A) and immunoblotting (Figure 5-4B); knockdown of one integrin
subunit did not lead to compensatory upregulation of others. In transwell motility assays,
knockdown of α9 attenuated chemotaxis on cFN (Figure 5-5A), whereas knockdown of
α5 or αv either had no effect or resulted in increased migration on both pFN and cFN
(Figure 5-5, B-C). Function blocking antibodies against the integrins yielded similar
results, with antibodies against α9β1, but not those against α5β1 or αvβ3 inhibiting
chemotaxis (compare Figure 5-5D with 5-5E and F).

Portal fibroblasts express minimal α9 integrin

Unlike stellate cells, portal fibroblasts did not demonstrate increased motility on
cFN (Chapter 4), so having now identified α9β1 as the integrin responsible for motility,
we hypothesized that portal fibroblasts might not express it. Indeed, while myofibroblasts
derived from stellate cells and portal fibroblasts express comparable levels of αv and α5
(Figure 5-6A), and neither cell type expresses α4 (data not shown), stellate cells express
approximately 15-fold more α9 than do portal fibroblasts at the equivalent stage of
differentiation (Figure 5-6A). Consistent with the qRT-PCR data, immunostaining of
fibrotic livers from mice that underwent bile duct ligation demonstrated many α9expressing cells in the sinusoidal region, but few in the portal scar (Figure 5-6B). As
expected, α9-expressing cells are also found in the sinusoidal region after
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αv
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Ppib

Figure 5-4. Integrin knockdown is effective. Four days after isolation, hepatic
stellate cells were transduced with 25 MOI of adenovirus expressing shRNA targeting
one of three integrin subunits or with a scrambled control. A. 72 hours posttransduction, integrin expression levels were measured by qRT-PCR. One of four
representative experiments is shown, and error bars represent standard deviation
from technical replicates. B. 72 hours post-transduction, integrin expression levels
were measured by immunoblotting. Results shown represent one of four
representative experiments. !
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Integrin blocking antibodies!
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Figure 5-5. !9"1 is responsible for increased chemotaxis on cFN. A-C. Hepatic
stellate cells were cultured for 4 days then transduced with an adenovirus expressing
either an integrin-targeting shRNA or a scrambled (scr) control. Transwell chemotaxis
assay was performed 72 hours post-transduction. D-F. Hepatic stellate cells were preincubated with blocking antibodies against "9#1, "5#1, or "v#3 for 1 hour prior to
beginning the transwell chemotaxis assay. Results are averaged from 3-4 independent
experiments. Error bars represent SEM from 3-4 independent experiments. * = p $
0.05. ** = p $ 0.01.!
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Figure 5-6. !9"1 is not highly expressed by portal fibroblasts. A. !9 expression
was measured in isolated primary hepatic stellate cells (HSC) or portal fibroblasts (PF)
differentiated to myofibroblasts in culture. B. !9 staining was performed on liver
sections from wild type mice that underwent bile duct ligation. !9 staining (blue)
exhibits a sinuosoidal pattern and is excluded from the portal area (outlined by yellow
line in right panel) with the exception of biliary epithelial cells. Scale bar = 50 "m. C. !9
staining was performed on liver sections from wild type mice mice that received
thioacetamide for 12 weeks. !9 staining (brown) exhibits a sinuosoidal pattern.
Sections are counterstained In hematoxylin (blue). Note that colors in (B) and (C) are
opposite. D. qRT-PCR for !9 expression was performed on whole liver lysates from
mice that received thioacetamide for 12 weeks.#
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thioacetamide treatment (Figure 5-6C). Interestingly, compared to wild type mice, EIIIA/-

mice had lower expression of α9 mRNA (Figure 5-6D), suggesting a potential role for

EIIIA in regulating α9 itself, though these data need to be confirmed at the protein level.
Collectively, these results suggest that the EIIIA/α9 interaction specifically
promotes motility of hepatic stellate cells and not portal fibroblasts. It follows that EIIIA/-

mice are protected in a model of liver fibrosis in which hepatic stellate cell motility is

likely to play a dominant role, thioacetamide, but not in a model in which portal
fibroblasts are the early responders and motility is not required (Figure 5-7).

α9 integrin is expressed in human liver disease

Our model predicts that α9 integrin-expressing cells would be found in scar tissue
in human liver diseases that feature a parenchymal injury pattern, such as alcoholic
cirrhosis or non-alcoholic steatohepatitis (NASH), but not in scar tissue in diseases that
feature a biliary injury pattern, such as biliary atresia, primary sclerosing cholangitis, or
primary biliary cirrhosis (Figure 5-7). We investigated α9 integrin localization in a small
panel of human liver diseases by immunohistochemistry (Figure 5-8). As expected, we
saw very few α9-expressing mesenchymal cells in portal scars in biliary diseases, though
biliary epithelial cells did appear to express α9. In contrast, some α9-expressing
mesenchymal cells, as well as biliary epithelial cells, were clearly seen in scar tissue in
liver sections from patients with autoimmune hepatitis, hepatitis B, or hepatitis C, which
feature a mixed biliary/parenchymal injury pattern. Unfortunately, despite heroic efforts
we were unable to obtain samples from patients with alcoholic cirrhosis or NASH, the
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Figure 5-7. EIIIA/!9"1 promotes hepatic stellate cell motility and non-biliary
fibrosis. A. The healthy liver is composed of the liver sinusoid, where hepatic stellate
cells reside, and the portal tract, where portal fibroblasts reside. B. In hepatic injury, as
modeled by thioacetamide administration, hepatic stellate cells become motile in an
EIIIA/!9"1 dependent manner. We predict that this process would be important in
human diseases that feature this type of injury, including alcoholic cirrhosis and nonalcoholic steatohepatitis (NASH). C. In biliary injury, as modeled by bile duct ligation,
portal fibroblasts are likely the first responders, and unlike stellate cells they do not
require EIIIA/!9"1. We predict that the same would be true in the human diseases that
feature this type of injury: biliary atresia, primary sclerosing cholangitis, and primary
biliary cirrhosis. #
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Figure 5-8. !9 staining in human diseases. Human liver sections were stained for !9
(brown) and with hematoxylin (blue). Diseases with a mixed parenchymal and biliary
pattern of injury, such as autoimmune hepatitis (AIH), hepatitis B (HBV), and hepatitis C
(HCV) are shown on the top panel. !9- expressing cells with a mesenchymal shape are
enlarged in the inset. Diseases with a biliary pattern of injury, such as primary
sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and biliary atresia (BA),
are on the bottom panel. Scale bar = 50 "m. "
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diseases that we would predict would have the greatest number of α9-expressing cells.

Discussion

Our data suggest that the mechanism by which cFN promotes stellate cell motility
does not involve PDGF-BB but rather α9β1 integrin signaling. An emerging body of
literature supports a role for α9β1 and EIIIA+ cFN in cell migration, although few studies
have examined the pair together. α9β1 has been reported to promote cell motility via
interactions with several ligands, including tenascin C (Gupta and Vlahakis, 2009;
Nakayama et al., 2010) osteopontin (Ito et al., 2009; Nakayama et al., 2010), nerve
growth factor (Staniszewska et al., 2008), and vascular cell adhesion molecule-1
(VCAM-1) (Taooka et al., 1999), although a common α9β1-binding epitope in these
ligands has not been identified. EIIIA+ cFN has been implicated in migration of epithelial
cells (Inoue et al., 2001) and rectal adenocarcinoma cells (Shimao et al., 1999), though no
receptor was identified in these studies.
Although relatively little is known about α9, there are preliminary reports
implicating three different pathways in promoting α9-mediated motility. First, α9expressing cells demonstrate increased nitric oxide (NO) production, with associated
increases in phosphorylation of inducible nitric oxide synthase (iNOS), and inhibiting
NO, iNOS, or guanylate cyclase decreases migration (Gupta and Vlahakis, 2009).
Second, treatment with Mn2+ has been shown to stimulate transition of α9 from a
motility-promoting, intermediate activation state, to an adhesion-promoting, high
activation state (Lydolph et al., 2009). Finally, spermidine/spermine acetyl transferase
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(SSAT) has been reported to bind to the cytoplasmic domain of α9, enhancing migration
(deHart et al., 2008). We have conducted preliminary experiments with chemical
inhibitors targeting each of these pathways, but in each case motility was inhibited to an
equivalent extent on both pFN and cFN (data not shown), so we have yet to identify a
factor responsible for propagating the EIIIA/α9 signal.
It is also possible that the primary effect of α9β1 and EIIIA+ cFN is not to directly
promote motility, per se, but rather to relieve a baseline inhibitory effect of α5β1 on
motility. Previous work from our lab suggests that α5β1 strongly promotes stellate cell
spreading (data not shown), a process that may be antagonistic to motility, and we show
here that α5β1 localizes to mature focal adhesions (Figure 5-3E) and that knocking down
α5 enhances stellate cell chemotaxis (Figure 5-5C). Indeed, while α5β1 has been
implicated as a pro-motility factor in many cell types, it has also been demonstrated to
promote adhesion at the expense of migration in systems as diverse as breast cancer cells
(Fang et al.; Sisci et al.), synovial fibroblasts (Lowin et al., 2009), CHO cells (Chen et al.,
2008; Ly et al., 2003), and periodontal ligament cells (Takemura et al., 2006).
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Chapter 6:
Spinning disc
(Work in progress)

Introduction

We have shown that α9β1 mediates a phenotype of increased motility on cFN.
Cell migration and adhesion are intimately linked, and we wondered if adhesion would be
different on pFN versus cFN. It has previously been demonstrated that adhesion to
fibronectin is proportional to the number of integrin bonds per cell (Boettiger, 2007).
Thus, it is possible that stellate cells would have greater adhesion to cFN than to pFN,
due to the fact that they can use an additional integrin (α9β1) to adhere to the matrix.
However, it is also possible that stellate cells would actually be less adherent to cFN, as
part of the process of cell motility involves breaking integrin bonds and rapidly turning
over focal adhesions. To differentiate between these two possibilities, we employed a
spinning disc assay, which provides a quantitative measurement of integrin-based
adhesion. This assay has several advantages compared to traditional “plate and wash”
assays, which use very weak forces to disrupt cells and therefore only measure the initial
phase of adhesion, dividing cells simply into “adherent” versus “non-adherent.” The
spinning disc assay allows measurement of adhesion over a much greater range of
applied forces, and if might allow use to directly demonstrate an EIIIA/α9β1 interaction,
rather than simply inferring it.
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Results

We hypothesized that the ability to bind cFN via not only the classical FNbinding integrins, α5β1 and αvβ3, but also via α9β1, would make cells more adherent to
cFN than to pFN. However, primary stellate cells, as well as 3 cell lines with a similar,
though not identical, integrin expression pattern to primary hepatic stellate cells (Table 61) demonstrated no difference in adhesion to pFN and cFN (Figure 6-1).
It is also possible that α5β1 and αvβ3 are the dominant FN-binding integrins, but
that α9β1 confers some additional adhesive activity when cells are challenged by blocking
α5β1 and αvβ3. We employed several strategies to block the classical integrins, including
treatment with snake venom disintegrins, cyclical RGDS peptide, integrin blocking
antibodies, and integrin knockdown. Initial experiments with echistatin, which blocks the
RGD-binding integrins (Table 6-2), were promising, in that stellate cells on cFN coated
coverslips appeared resistant to even high doses of echistatin, whereas those on pFN were
not (Figure 6-2A). This result was confirmed using another disintegrin that also inhibits
the RGD-binding integrins but with higher affinity, VLO4 (Figure 6-2B). Finally, treating
with a control disintegrin, obtustatin, that blocks the collagen-binding integrin α1β1 had
no effect on adhesion to either pFN or cFN (Figure 6-2C), and treating with either
echistatin or obtustatin had no effect when cells were plated on a mixture of fibronectin
and collagen (Figure 6-2D). These data suggested that the disintegrins were working
specifically and that stellate cells remain somewhat adherent to cFN even after inhibition
of the RGD-binding integrins, possibly because of α9β1.
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α4

α9

α5

αv

Primary HSC

-

+

+

+

LX2

-

+

+

+

RD

+

+

+

Low +

L6

Low +

+

+

-

Table 6-1. Integrins expressed by primary hepatic stellate cells (HSC) versus cell
lines. Integrin expression was measured by flow cytometry for RD cells, by western
immunoblotting for LX2 cells, and by both methods for primary stellate cells and L6
cells (primary data not shown).
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Figure 6-1. Adhesion to pFN and cFN is equivalent. Spinning disc assay was
performed using primary stellate cells, the LX2 human stellate cell cell line, the
human RD cell line, or the rat L6 cell line. Cells were allowed to adhere to FN-coated
coverslips for 1 h at 30° C, then spun at 4,000-5,000 rpm for 5 minutes. After the spin,
cells were fixed, stained with DAPI, and counted. !50 (dynes/cm2) was determined
using SigmaPlot software. Error bars represent SEM from 6 independent experiments
for primary hepatic stellate cells, 4 independent experiments from LX2 cells, and 2
independent experiments for RDs cells. Only one experiment included L6 cells. !

94

Disintegrin

Integrins blocked

Echistatin

α5β1 and αvβ3

VLO4*

α5β1, αvβ3, and α4β1**

VLO5

α9β1 and α4β1**

Obtustatin

α1β1

* VLO4 has higher affinity for α5β1 than does echistatin
** not expressed in stellate cells
Table 6-2: Integrins blocked by snake venom disintegrins.
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Figure 6-2. Adhesion to pFN and cFN after blocking RGD-binding integrins.
Spinning disc assay was performed as described in the previous figure. A. Primary
stellate cells were plated on FN-coated coverslips in the presence of increasing
doses of echistatin. Each dose of echistatin represents an independent experiment.
The vehicle result is averaged from the 3 experiments. Error bars represent SD. B.
Primary stellate cells were plated on FN-coated coverslips in the presence of 5 !M
VLO4. Error bars represent SD from a single experiment. C. Primary stellate cells
were plated on FN-coated coverslips in the presence of 300 nM obtustatin. Results
are averaged from 3 experiments, and error bars represent SEM. D. Primary stellate
cells were plated on a mixture of FN and collagen in the presence of 300 nM
echistatin and 300 nM obtustatin. Error bars are SD from a single experiment.!

96

Based on the dose response curve in Figure 6-2A, we chose to proceed with an
intermediate dose of echistatin (100 nM) for future studies. Unfortunately, in three
independent experiments, treating stellate cells with 100 nM echistatin had a comparable
(and modest) effect on both pFN and cFN (Figure 6-3A). Additionally, in the LX2 human
stellate cell line, echistatin and VLO4 inhibited adhesion to an equivalent extent on pFN
and cFN (Figure 6-3B), raising question as to whether there is any real difference in
adhesion of stellate cells to pFN and cFN.
Concerned about the specificity of the disintegrins and the reproducibility of these
results, we employed additional means of inhibiting RGD-binding integrins. First, we
treated cells with cyclic RGDS peptide or a control RGES peptide. Surprisingly, RGDS
completely abolished adhesion to cFN, yet had no effect to on pFN (Figure 6-3C).
Second, we tried α5β1 blocking antibodies, which had no effect on primary stellate cells
on either pFN or cFN (Figure 6-3D), but markedly decreased adhesion on both pFN and
cFN in the human LX2 stellate cells (Figure 6-3E). Finally, knocking down α5 or α5 and
αv together had little effect on adhesion of primary hepatic stellate cells to either matrix
(Figure 6-3F).

Discussion

Using both primary stellate cells and various cell lines, we observed no difference
in baseline adhesion to pFN and cFN. We then challenged cells by inhibiting the classical
FN-binding integrins, α5β1 and αvβ3. Attempting to manipulate a parameter in this assay,
such as blocking an integrin, could conceivably generate four possible results: 1. There
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Figure 6-3. Differential effects of integrin blocking techniques. Spinning disc
assay was performed as described in the previous figures. A. Primary stellate cells
were plated on FN coated coverslips in the presence of 100 nM echistatin. Results
are averaged from 3 experiments and error bars represent SEM. B. LX2 human
stellate cells were plated with echistatin and/or VLO4. Vehicle and echistatin were
used in 3 experiments, but VLO4 was only added in one. Error bars represent SEM
from the 3 experiments and are thus excluded from the VLO4 conditions. C.
Primary stellate cells were treated with cyclic RGDS or control RGES peptides prior
to spinning. Error bars represent standard deviation from a single experiment. D.
Primary stellate cells were incubated with !5 blocking antibodies. Error bars reflect
SEM from 3 independent experiments. E. LX2 human stellate cells were
preincubated with !5 blocking antibodies. Results represent 3 independent
experiments, and results reflect SEM. F. Integrins were knocked down 3 days prior
to spinning. Results are averaged from 2 independent experiments, and error bars
reflect SEM. !
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could be no change in adhesion to either pFN or cFN. 2. There could be a selective
change in adhesion to pFN. 3. There could be a selective change in adhesion to cFN. 4.
There could be an equivalent change in adhesion to both pFN and cFN. Although initial
experiments seemed to demonstrate a selective change in adhesion to cFN, in the
subsequent experiments presented in Figure 6-3, we observed every one of these 4
theoretical outcomes after trying to inhibit the RGD FN-binding integrins. Thus, at this
time, no firm conclusions can be drawn as to the requirement of various integrins for
adhesion to pFN and cFN.
During the course of these experiments, many technical difficulties were
encountered, the largest of which was our persistent inability to obtain enough primary
hepatic stellate cells to do these experiments in the way they were intended. Stellate cells
represent a minority cell population in the liver, and they do not proliferate in culture, so
cell number is a limiting factor. To generate reliable data for the spinning disc, cells must
be plated densely on the coverslip and each experimental condition must be performed in
triplicate. In many cases, these conditions were not met due to low cell number. To try to
overcome this issue, we employed various cell lines, but this raises the additional concern
that cell lines may not mimic the behavior of primary cells; indeed, the degree to which
stellate cell lines are an appropriate model for primary cells has been an area of
controversy (Herrmann et al., 2007). An additional technical problem was that in some
experiments, the treatment designed to block integrin-mediated adhesion during the spin
actually prevented many cells from ever adhering to the coverslip at all. That is, they
detached even prior to the spin, and whether the remaining cells were representative is
unknown.
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Beyond technical issues, there are also many scientific reasons why we might
have failed to consistently detect α9β1-mediated adhesion to cFN, and we will discuss
several of these here. Each of the hypotheses advanced is widely speculative, given the
very small body of literature on both EIIIA+ cFN and α9β1, but each is also testable.
First, it is possible that the reported EIIIA/α9β1 interaction is merely an artifact. The fact
that specific amino acids mediating the interaction have been identified (Shinde et al.,
2008) as well as the fact that individually blocking either EIIIA or α9β1 results in a the
same phenotype (Chapter 5) argues against this possibility, but future studies to
determine the veracity and specificity of the interaction may be warranted.
If we assume that the EIIIA/α9β1 interaction is real, another potential explanation
for our findings might involve the fact that α9 and α5 share the same β subunit, β1. If
expression of β1 was the limiting factor in determining how many integrin dimers were
localized to the cell surface, and α9 and α5 competed for binding to a finite pool of β1
subunits, then perhaps cells on cFN would simply have a higher ratio of α9β1 to α5β1 on
the cell surface, rather than a greater total number of integrin dimers available for binding
to FN. Indeed, competition between β1 and β8 for αv, which binds several β1 subunits, has
been documented in 293 cells (Moyle et al., 1991). This hypothesis could easily be tested
by over-expressing β1.
It is also possible that there is an additional factor present in our motility
experiments that is required for the EIIIA/α9β1 interaction, and this factor is absent in the
spinning disc experiments. The spinning disc experiments are performed over a short
duration (1 h) in a simple buffer (1M HEPES pH 7.4, 5 M NaCl, 0.1 M KCl, 1 mM
MgCl2, 200 mM glucose). In contrast, the transwell chemotaxis experiments are
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performed overnight in M199 media, supplemented with 10% FBS in the bottom
chamber. Serum contains a huge number of unknown factors, any of which could
potentially alter localization, post-translational modification, or activation state of α9.
There is a precedent for post-translational modifications of integrins regulating their
substrate specificity, as phosphorylation of αvβ3 promotes binding to vitronectin
(Boettiger et al., 2001a; Boettiger et al., 2001b) but is actually a negative regulator of
binding to fibronectin (Datta et al., 2002).
Yet another possible explanation for our findings would be if cFN did not adsorb
to the glass substrate as well as pFN. It has been shown that integrin binding is directly
proportional to ligand density (Garcia and Boettiger, 1999), so if cells were using α9β1 to
adhere to cFN but there was less cFN present, this would also explain our results. We
used a high concentration of FN, 20 µg/ml, shown to be above the saturating range for
pFN (Garcia and Boettiger, 1999), to try to eliminate this concern, but we did not directly
quantify pFN and cFN adsorption to glass, and thus differences in this parameter cannot
be excluded.
Finally, given that stellate cells have a motile morphology on cFN-coated
polyacrylamide gels but not on cFN-coated plastic, it is possible that the EIIIA/α9β1
interaction does not occur on stiff substrates. However, arguing against this explanation is
the fact that the transwell inserts are artificially stiff yet still promote EIIIA/α9β1
mediated motility (Chapters 4 and 5), and the fact that the EIIIA/α9β1 interaction was
first identified in cells cultured on plastic (Liao et al., 2002).
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Chapter 7:
Discussion

Summary of work

The goal of this work was to determine the requirement for EIIIA+ cFN in hepatic
stellate cell myofibroblast differentiation and liver fibrosis. We show here that (male)
EIIIA-/- mice are protected from thioacetamide-induced, but not bile duct ligation-induced
liver fibrosis, and we propose that this difference is due to a differential requirement for
EIIIA+ cFN for two myofibroblast precursor populations: hepatic stellate cells and portal
fibroblasts, which are the first responders in parenchymal versus biliary injury,
respectively. Surprisingly, EIIIA+ cFN was not required for myofibroblast differentiation
of either cell type, but rather promoted a motility phenotype in hepatic stellate cells. In
chapter 5, we demonstrate that cFN-enhanced motility is independent of PDGF-BB, but
instead requires α9β1 integrin, which is not highly expressed by portal fibroblasts.
Finally, we conclude with a brief examination of adhesion to pFN and cFN, presenting
preliminary data that suggest that the α9β1/EIIIA interaction does not confer measurably
increased adhesion to cFN.
The results presented here have important implications for understanding and
treating non-biliary fibrosis. The most common causes of liver fibrosis in adults are not
cholestatic diseases but rather hepatotoxic and inflammatory diseases with a mixed or
parenchymal pattern of injury, including alcoholic liver disease and chronic viral
hepatitis, for which hepatic stellate cell motility may be pathologically important.
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Function blocking antibodies already exist for both EIIIA and α9β1, and a better
understanding of downstream signaling effectors of α9β1, may suggest other inhibitors
(deHart et al., 2008; Gupta and Vlahakis, 2009; Lydolph et al., 2009). EIIIA (although
not α9β1) has a restricted tissue distribution pattern in healthy adults, which could
potentially minimize toxic effects of inhibition. For these reasons, EIIIA and α9β1
represent attractive, novel therapeutic targets for human liver fibrosis.
EIIIA+ cFN has been widely cited as an absolute requirement for myofibroblast
differentiation, despite relatively little evidence for this claim. Our work refutes this, at
least insofar as we show that EIIIA+ cFN is not required for upregulation of αSMA, the
quintessential myofibroblast marker, by either hepatic stellate cells or portal fibroblasts,
or in either of the fibrosis models we used. Preliminary data suggest that EIIIA is also not
required for myofibroblast differentiation in a third model of fibrosis, CCl4 (data not
shown). While we are not the first to suggest the lack of a direct correlation between
EIIIA and αSMA expression (Astrof et al., 2004), we are the first to do so for
myofibroblasts.
This work is also novel in that it is among the first to demonstrate that the
EIIIA/α9β1 interaction has any functional significance (Bazigou et al., 2009; Ou et al.),
and it is the very first to demonstrate that it increases cell motility. (One previously
published report had also suggested that the interaction led to increased motility in
pulmonary cells undergoing epithelial to mesenchymal transition, but it has been
retracted due to fraudulent data (Sun et al.) 2010)).
Our work is also unique in combining the study of cellular fibronectin with the
polyacrylamide gel system. pFN has been frequently used as an adhesive coating on
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polyacrylamide gels, but cFN is widely ignored, despite the fact that it constitutes 50% of
the fibronectin pool in healthy tissues (Moretti et al., 2007), and an even greater
percentage in disease states. As discussed in greater detail in chapter 4, fibronectins are
mechanosensitive proteins, and using them on tissue culture plastic or glass may result in
non-physiologic, or at the very least, different conformations of the protein (Garcia et al.,
1999) than using them on soft supports. Additionally, many groups have focused on
using fibronectin fragments rather than full-length fibronectin, which are easier to work
with due to their smaller size, but which may not behave similarly to the full length
protein (Manabe et al., 1997).
We believe that the use of full-length pFN and cFN on polyacrylamide supports
makes our system more physiologic than many, and this may explain why our results
differ from previous reports in terms of the role of cFN in myofibroblast differentiation of
stellate cells (Jarnagin et al., 1994). Unfortunately, no system is perfect, and this very
advantage may ironically also constitute one of the weaknesses of the work. As
previously discussed, pFN and cFN differ from each other in several ways, in addition to
alternative splicing, and purchasing them from commercial sources has drawbacks. They
are, by definition, purified from different sources, and lot-to-lot variability in the
purchased product is a significant concern. To investigate these issues, we performed
western immunoblotting on pFN and cFN from various commercial sources (Figure 7-1).
In addition to bands at the predicted size of the FN dimer or monomer, we saw several
smaller bands, likely representing degradation products of FN. While these bands were
present to some extent in all samples, they were especially prominent in cFN.
Additionally, while we confirmed that only cFN contains EIIIA (Figure 4-2), we have
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commercial source is indicated. !
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no way of determining how many individual isoforms contain EIIIA, and it has been
estimated by others that as few as 25% of dimers in commercial cFN include EIIIA on
both chains (Manabe et al., 1997). We also have no way of determining whether cFN
includes EIIIB, given the lack of a commercially available EIIIB antibody, though we are
in the process of obtaining an EIIIB antibody from a collaborator.
When these considerations are taken into account, it is clear that this is not a clean
system, and what we gain in physiologic rigor, we may lose in reproducibility of
experiments. To overcome this, we have generated stable cell lines expressing each fulllength recombinant cFN splice variant, as described in chapter 2. Work to purify the
fibronectin from these cells is ongoing, and it is our hope that combining the use of pure
recombinant full-length cFN isoforms with the polyacrylamide gels will allow us to
continue with a physiologically relevant system, while simultaneously maximizing
reproducibility.
Another potential theoretical concern with our in vitro culture system is the fact
that stellate cells themselves produce some EIIIA+ cFN (Chapter 4), and pFN present in
fetal bovine serum may also be capable of incorporating into FN fibrils (Hayman and
Ruoslahti, 1979). Although we have demonstrated that these two sources of fibronectin
are small enough to be undetectable by western blotting (data not shown) and do not
seem to be appreciably added to the original fibronectin coating on the gel (Figure 4-4),
an immediate priority is to repeat key experiments using fibronectin-depleted serum and
stellate cells isolated from the EIIIA-/- mice to definitively confirm that EIIIA is not
required for myofibroblastic differentiation.
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Future directions

Further defining the role of α9β1 integrin

We have demonstrated that EIIIA-/- mice fail to develop fibrosis after treatment
with thioacetamide, which is an encouraging finding that raises many other questions.
First, is it possible to achieve some therapeutic effect by inhibiting EIIIA after the
process of fibrosis has already started? EIIIA is upregulated very early on during liver
injury, so it is possible that its therapeutic window would be too narrow to be useful
clinically. Future studies should directly investigate whether inhibiting EIIIA has any
beneficial effect on established fibrosis.
Second, if EIIIA is indeed acting through its specific receptor, α9β1, does
inhibiting α9β1 also prevent the development of TAA-induced fibrosis? We should not
necessarily assume that this so, as α9β1 binds several ligands besides EIIIA; thus
blocking α9β1 is unlikely to exactly phenocopy blocking EIIIA in vivo. One method for
testing this would be to use the adenoviruses expressing α9-targeting shRNAs that we
already have. Adenoviruses are known for robust expression in liver, and these could be
administered to mice by tail vein injection concomitantly with thioacetamide treatment.
Alternatively, we could take a genetic approach. α9-/- mice die shortly after birth due to
bilateral chylothorax (Huang et al., 2000), making them unsuitable for this type of study,
but α9+/- mice survive to adulthood, and the recent generation of mice with a floxed α9
allele (Bazigou et al., 2009; Singh et al., 2009) also opens up the possibility of a tissue
specific knockout.
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Third, what cellular events are mediating the motility phenotype downstream of
the EIIIA/α9 interaction? We have begun with a candidate approach, based on the very
few published reports on α9, but this has thus far been unsuccessful in identifying a target
that is specifically responsible for motility on cFN. Thus far, we have relied on the
transwell chemotaxis assay to screen for downstream mediators, but a parallel approach
could involve examining focal adhesion size and composition, cell shape, or random
motility on hydrogels after α9 knockdown.
Given the relative dearth of knowledge about α9, casting a wide net may be the
best way to identify downstream targets. After we are able to purify recombinant cFN
isoforms, we would like to perform a whole genome microarray using stellate cells
cultured on EIIIA- cFN, EIIIA+ cFN, and EIIIA+ EIIIB+ cFN. This will enable us to
identify transcripts that are uniquely regulated by EIIIA, some of which will likely be
involved with the α9-mediated motility phenotype. Of course, many cellular motilitypromoting events occur not at the level of transcription but rather involve
phosphorylation of proteins, cycling of small GTPases, or reorganization of the
cytoskeleton, none of which will be captured by a microarray. However, the small scale
of our system (post-mitotic primary stellate cells on polyacrylamide gels) limits our
ability to do any sort of proteomic analysis, and we are confident that the relatively slow
nature of stellate cell migration (hours to days) suggests some role for transcriptional
regulation.

Studying migration in vivo
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We have demonstrated that stellate cells cultured on cFN in vitro do not have
increased myofibroblast differentiation, but rather have increased motility, which
depends on EIIIA and α9β1. We have also demonstrated that (male) EIIIA-/- mice are
protected from thioacetamide-induced fibrosis, and we infer that this is due to impaired
stellate cell motility in the absence of EIIIA. However, this conclusion involves a bit of a
logical leap, and neither we nor any other group have definitely demonstrated that stellate
cell motility, per se, is really required for the development of liver fibrosis.
One increasingly popular idea is that stellate cell motility is important for liver
fibrosis because of stellate cell’s unique role as liver-specific pericytes (Wirz et al.,
2008). Motility of both pericytes and endothelial cells is required for angiogenesis, which
is in turn required for fibrosis (reviewed in (Lee et al., 2007)). There is mixed evidence
with respect to a requirement for EIIIA and EIIIB in angiogenesis, (Khan et al., 2005;
Astrof et al., 2004), perhaps because of redundancy in their functions (Astrof et al.,
2007), but emerging literature more strongly supports a role for EIIIA and α9β1 in
lymphogenesis. α9 knockout mice die in the early post-natal period due to chylothorax
(Huang et al., 2000), and mice with a lymphatic-specific knockout of α9 have impaired
lymphatic valve morphogenesis, a result which is partially phenocopied by the EIIIA-/mice (Bazigou et al., 2009). The EIIIA/α9β1 interaction has also been suggested to
promote lymphogenesis in colon cancer (Ou et al., 2010), a process which may be
inhibited by endostatin (Ou et al., 2011). Finally, Nakayama et al. demonstrate that α9β1
is required for formation of granulation tissue during wound healing. When α9 is blocked
in dermal myofibroblasts they fail to migrate into wounds, and the wounds have
decreased CD31 staining suggesting impaired angiogenesis or lymphogenesis;
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importantly, there is no defect in myofibroblast differentiation, only motility (Nakayama
et al., 2010). Fortunately, there are many known endothelial makers with available
antibodies as well as well-established tubulogenesis assays for studying angiogenesis and
tubulogenesis, making this an easy avenue to pursue.
Trying to study cell motility directly in vivo (rather than using angiogenesis or
lymphogenesis as a presumed indicator of cell motility) is not a trivial task, so it is
unsurprising that more progress has not been made in this regard. Much work comes
from the fields of cancer biology or developmental biology, in which cells undergo longrange migrations to entirely new tissues, and a requirement for motility can be inferred
simply by observing a cell type in a new tissue. Fortunately, there are some emerging
tools that may make studying short-range motility, within an organ, more feasible. The
first of these tools is the use of precision cut tissue slices, which allow culture of a tissue
for a period of days. This is still not a truly in vivo system, but does provide the
investigator with the ability to study cells in situ, with preserved cell-cell and cell-matrix
interactions in the context of their native microenvironment. Precision cut liver slices
have actually been in use since the mid-1980’s (Smith et al., 1985), but only recently are
they becoming more popular (Gonzalo et al., 2007; Guyot et al., 2007), as culture
conditions are being worked out to allow the slices to survive for longer and the cost of
tissue slicers becomes less prohibitive.
Another exciting tool for studying cell motility in vivo is the recent creation of the
“Brainbow” mouse, which uses Cre/lox recombination and transgenic technology to
stochastically create tandem inserts of 3 or more fluorescent proteins, ultimately labeling
cells with 90 different specific colors (Livet et al., 2007). Using this technology and
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time-lapse confocal microscopy, it is possible to track the motility of individual neurons
over time in vivo for up to 50 days (Zuo et al., 2004). Several Brainbow transgenic lines
are commercially available and can be crossed to any tissue-specific Cre line. However,
one caveat to applying this technology to stellate cells is that there is no perfect stellate
cell marker, so multiple lines would likely need to be created and compared (Van de
Bovenkamp et al., 2007). Additionally, the optics of the liver are quite different than
those of the brain, which could prohibit imaging in vivo in live animals. Nonetheless, if
combined, the use of the Brainbow mouse and precision cut liver slices could make for a
very powerful tool for studying cell motility in situ, and this would represent an
enormous advance compared to currently available in vitro technologies (transwell
motility assays and time-lapse microscopy of cultured cells).

Other effects of EIIIA in vivo

Although we have focused primarily on the role of EIIIA+ cFN in myofibroblast
differentiation and behavior, there is no reason to think that it might not have additional
effects in vivo. EIIIA has been demonstrated to be a ligand for Toll-like receptor 4
(TLR4) (Okamura et al., 2001), and this interaction promotes inflammation in a mouse
model of rheumatoid arthritis (Gondokaryono et al., 2007). Although we did not observe
a significant inflammatory infiltrate in either the thioacetamide or bile duct ligation
model of fibrosis, we cannot yet rule out a role for EIIIA/TLR4 interaction, particularly
as TLR4 is known to be important for development of fibrosis ((Seki et al., 2007) and
reviewed in (Pradere et al., 2010) and fibrosis-associated angiogenesis (Jagavelu et al.,
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2010).

The role of EIIIB in liver fibrosis

We observed that EIIIB+ cFN was upregulated in both models of fibrosis at the
later time point (Figure 3-5B, Figure 3-9F). Additionally, a post doc in the lab has
demonstrated that EIIIB+ cFN is basally expressed by portal fibroblasts isolated from
healthy rat livers, and it also upregulated by portal fibroblasts very soon after liver injury
in rats given CCL4 or undergoing bile duct ligation (data not shown). These preliminary
observations suggest that EIIIB+ cFN might be especially important in the portal tract of
the liver, either in healthy animals or in response to injury, and it is tempting to
hypothesize that the reason that EIIIA-/- mice were not protected from bile duct ligation
induced fibrosis is due partly to compensation by EIIIB+ cFN. The fact that we did not
yet see an upregulation of EIIIB at 6 days after bile duct ligation, by which the EIIIA-/mice and wild type mice had already developed equivalent fibrosis, might argue against
this hypothesis, but it is also possible that EIIIB was upregulated specifically in the portal
area and sensitivity was too low to detect it in whole liver lysates.
EIIIB-/- mice are not commercially available, but we expect to be able to obtain
them from a collaborator, and it would be interesting to examine their susceptibility to
liver fibrosis, particularly using the bile duct ligation model or other biliary models. It
would also be interesting to examine fibrosis susceptibility in EIIIA-/-/EIIIB-/- double
knockout mice; while 80% of these mice succumb to severe cardiovascular effects of a
129S4 strain background, only 50% do on a C57/Bl6 strain background, with the rest
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surviving to adulthood (Astrof et al., 2007). Still another possibility would be to use
double heterozygous mice, which are phenotypically normal.

Summary

The work presented here represents the first mechanistic description of the role of
EIIIA in liver fibrosis. It is by no means comprehensive, but rather a jumping off point
for future studies. Immediate future directions involve strengthening our results by
repeating critical experiments using pure recombinant FN isoforms and stellate cells
derived from EIIIA-/- mice. Longer term future directions could include further defining
the requirements for α9β1 in fibrosis, as well as identifying its downstream targets,
developing novel techniques for studying cell motility in situ or in vivo, and
characterizing the role of EIIIB+ cFN in liver fibrosis, particularly in biliary models. It is
our hope that these studies and many others will pave the way toward a better
fundamental understanding of the chemical and mechanical contributions of the ECM in
fibrosis, and ultimately lead to the generation of new therapeutic targets in an otherwise
nearly untreatable set of diseases.
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